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Necrotizing enterocolitis (NEC) is the leading cause of gastrointestinal-related 
mortality in premature infants and we have previously shown it develops, in part, under 
conditions of exaggerated Toll-Like Receptor 4 (TLR4) signaling and expression in the 
preterm newborn intestinal epithelium. Because NEC does not develop spontaneously, 
despite the presence of seemingly tonic stimulation of intestinal TLR4 by commensal 
flora in the newborn, we hypothesized that mechanisms must exist to constrain TLR4 
signaling that become diminished during NEC pathogenesis. Microarray analysis of 
murine ileal tissue from animals subjected to a model of NEC demonstrated a sharp 
decrease of expression of the intracellular stress response protein and chaperone Heat 
Shock Protein-70 (HSP70). We demonstrate that the induction of intracellular HSP70 in 
enterocytes dramatically reduced TLR4 signaling, as assessed by LPS-induced NF-κB 
translocation, cytokine expression, and apoptosis. These findings were confirmed in vivo, 
using mice that either globally lacked HSP70 or overexpressed HSP70 specifically within 
the intestinal epithelium. TLR4 activation itself significantly increased HSP70 expression 
in enterocytes, which provided a mechanism of autoinhibition of TLR4 signaling in 
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enterocytes. In seeking to define the mechanisms involved, intracellular HSP70-mediated 
inhibition of TLR4 signaling required both its C-terminal co-chaperone-binding EEVD 
domain and association with its co-chaperone CHIP, an E3 ligase responsible for the 
targeted ubiquitination and proteasomal degradation of TLR4. The expression of HSP70 
in the intestinal epithelium was significantly decreased in murine and human NEC 
compared with healthy controls, suggesting that loss of HSP70 protection from TLR4 
could lead to NEC. In support of this, intestinal HSP70 overexpression in mice and 
pharmacologic up-regulation of HSP70, via Celastrol, reversed TLR4-induced cytokines, 
TLR4 expression, enterocyte apoptosis, as well as prevented and treated experimental 
NEC in an HSP70-dependent manner. Thus, these data shed light upon a novel TLR4 
regulatory pathway within the newborn intestinal epithelium involving HSP70 that may 
be pharmacologically activated to prevent and/or limit NEC severity. 
Keywords: 
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Response, Chaperone, Heat Shock Proteins, ER stress, Unfolded Protein Response, 
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1.0	   INTRODUCTION	  
1.1 INNATE	  IMMUNITY	  
The immune system is composed of a series of biological mediators both, cellular and 
humoral, primarily aimed at combating invading pathogens in order to not only return the 
organism to homeostasis but to maintain it as well (1). The immune system is divided into two 
major arms: the innate and adaptive. The adaptive or acquired arm consists of a host of 
specialized cells arising from the lymphoid cell lineage in hematopoiesis. Comprising this 
cellular group are the CD4+ and CD8+ T cells along with B cells chiefly responsible for 
antibody production (2,3). These members of the adaptive immune system possess a large and 
unique repertoire of antigen receptors that maintain the impressive ability to recognize a wide 
array of specific antigens and induce the clonal expansion of those lymphocytes possessing the 
critical antigen receptor specific to an invading pathogen (1). The ability of the immune system 
to mount a specific and directed clonal expansion and honed immune response to a particular 
invading pathogen bears the significant cost of time. An effective adaptive immune response 
may require 3 to 5 days, which would leave the organism dangerously vulnerable if it were not 
for the “first-line” of host defense: the innate immune system. The innate immune system is in 
fact the evolutionarily older arm of the immune system from which the adaptive arm sprouted 
and exists in nearly all multicellular organisms (1). The innate immune system, like the adaptive 
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arm, consists of both cellular and innate humoral factors, which are capable of responding to and 
attenuating a wide variety of invading pathogens (Figure 1). The ability of the host to recognize 
invading pathogens is a fundamental event that must take place rapidly if clearance of the 
invader and a return to homeostasis is to occur. This rapid recognition and response to invading 
microbes occurs primarily via a group of microbial recognition receptors known as Pattern 
Recognition Receptors (PRRs) which maintain the ability to recognize evolutionarily conserved 
microbial motifs termed Pathogen-Associated Molecular Patterns (PAMPs) (4). The PRRs serve 
as sentinel receptors upon the cells of the innate immune system comprising a majority of their 
ability to recognize microbial invaders and initiate an effective immune response. Following 
PAMP-PRR recognition a beautifully well coordinated signaling and response cascade is 
initiated culminating in the generation of antimicrobial agents such as reactive oxygen and 
nitrogen species alongside the generation and release of cytokines and chemokines aimed at the 
activation and recruitment of neighboring immune cells. Furthermore, released cytokines and 
chemokines result in up-regulation of adhesion molecules on both the endothelium and immune 
cells to facilitate immune cell recruitment. PRR signaling also gives rise to induction of acute 
phase protein production, which comprises a family of proteins with varying physiological 
functions for the immune system including antimicrobial agents (e.g. C-Reactive Protein and 
Complement factors), pro-coagulant factors, as well as negative regulators to ensure attenuation 
of the immune response following clearance of the inciting pathogen (5). Additionally, the two 
arms do not exist separately from one another and are in fact heavily integrated. As elegantly 
demonstrated by Medizhtov and Janeway(6), PRR stimulation leads to a significant up-
regulation of co-stimulatory molecules critical to T cell activation and initiating crosstalk 
between the innate and adaptive immune system. 
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Figure 1.Cellular components of both the innate and adaptive arms of the immune system. The innate immune 
system is comprised macrophages, dendritic cells, mast cells, neutrophils, eosinophils, basophils and NK cells which 
initiate and mediate the rapid response to invading pathogens. The innate immune system comprises the front line of 
defense allowing the cells of the adaptive immune system, CD4 and CD8 T cells and B cells, to mount a slower but 
specific and directed immune response characterized by clonal expansion of lymphocytes and immune antigenic 
memory generation and maintenance. Figure reprinted by permission of Macmillian Publishers Ltd: Nature Reviews 
Cancer. Article: (7). Copyright 2004 
1.1.1 Toll-­‐like	  Receptors	  
The first group of PRRs to be discovered and subsequently the best characterized were 
the Toll Receptor family. Initially, Toll Receptors were identified and classified in Drosophila as 
playing a fundamental role in mounting antifugal immune responses in adults and in the 
signaling cascade regulating dorsoventral polarity in the fruit fly embryo (8). Shortly after this 
characterization, the human homologue of the Drosophila Toll receptors, named the Toll-like 
Receptor (TLR) were identified as playing an important role in crosstalk between the innate and 
adaptive immune system (6). To date a total of 10 and 12 TLRs have been identified in humans 
and mice respectively (4). The first PRR-PAMP identification was mapped to TLR4 as bacterial 
endotoxin lipopolysaccharide (LPS) derived from the cell wall of Gram-negative bacteria (6,9). 
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Subsequent identification of distinct PAMP recognition has been delineated and extended to 
various PAMPs derived from viruses, bacteria, mycobacteria, fungi and parasites for all TLRs 
except for human TLR10 and mouse TLR12 and 13 (4). These include lipoproteins (TLRs1, 2, 
6), double-stranded RNA (TLR3), Flagellin (TLR5), single-stranded RNA (TLR7, 8) and DNA 
(TLR9) (10) (Figure 2). The TLRs are a group of type I transmembrane proteins that bear a 
horseshoe-like solenoid shaped ectodomain containing 16-28 tandem leucine-rich repeats, which 
are important for ligand recognition, (11-14). The ectodomain sequences of the TLRs are 
strikingly similar despite the vast diversity of ligands they are capable of recognizing. One 
manner by which this diversity manifests is via amino acid variations within the leucine-rich 
modalities (LxxLxLxxN) (4). TLRs also bear a single transmembrane domain and a cytoplasmic 
Toll/IL-1 receptor (TIR) domain (15), so named as the TIR domain consists of roughly 150 
amino acids which display homology with the IL-1 receptor, which is important for the actual 
adaptor protein recruitment that are fundamental to the signal propagation of the TLRs. TLRs 
occur as dimers (16). A number of TLRs have been shown to form heterodimers (TLR1-TLR2, 
TLR2-TLR6, TLR8-TLR7 or TLR9) while others (TLR3, TLR4 and TLR9) have been shown to 
homodimerize (17,18). TLR dimers are believed to exist pre-assembled in a low-affinity 
complex prior to ligand binding. Upon ligand binding to symmetrically dimerized ectodomains, a 
conformational change is believed to occur, positioning the two TIR domains in closer proximity 
and yielding a suitable platform for the formation of an adaptor protein signaling complex that 
subsequently leads to activation of specific transcription factors (17). Most TLRs exists as 
surface bound receptors, however a small number (TLR3, TLR7 and TLR9) are localized 
intracellularly within endosomes as illustrated in Figure 2. 
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Figure 2.Classical TLR localization and PAMP recognition. Plasma membrane localized TLRs include TLR2, 
TLR4, TLR1/2, TLR2/6, TLR5 and TLR11. Endosomal TLRs include TLR3, TLR9 and TLR7. All TLRs signaling 
through the adaptor MyD88 except for TLR3 (TRIF only) and TLR4 (both MyD88 and TRIF). Figure reproduced 
with permission of Biochem J. Article: (10). Copyright: the Biochemical Society. 
In addition to the TLRs, additional members of the PRR family include Nucleotide-
binding oligomerization domain-like Receptors (NLRs) which detect DAP-type tripeptide motifs 
(NOD1) and muramyl-dipeptide motifs (NOD2) of peptidoglycan and cytosolic helicases Rig-I-
Like receptors (RLRs) which sense the presence of RNA(19). Both NOD1 and NOD2 have been 
demonstrated to cooperatively protect the colonic epithelium during bacterial infection (20,21) 
and specific deficiencies in NOD2 expression has been demonstrated to lead to Paneth cell 
dysfunction (discussed later) and significant intestinal injury (22,23). Additionally, a second 
group of NLRs exists which, instead of leading to immune transcriptional responses, leads to the 
activation of the inflammasome, a process integral to the activation of two specific cytokines that 
are critical supporters of host mucosal defense: pro-IL-1B and pro-IL-18 (19). It is noteworthy to 
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recognize not only the diversity but the impressive redundancy among the PRRs in terms of both 
PAMP/DAMP recognition and signaling cascades.  
1.1.2 Adaptor	  Proteins	  and	  TLR	  signaling	  Cascades	  
Of the various adaptor proteins containing TIR domains, two fundamental members 
include Myeloid Differentiation primary response gene 88 (MyD88) and TIR-containing 
adaptor-inducing interferon-b (TRIF) (10,17). Adaptor proteins are also implicated in adding to 
the complexity and diversity of TLR signaling in how they associate with the TIR domains of the 
various TLRs in response to ligand binding (4). MyD88 is generally viewed as the universal 
adaptor for the TLRs (excluding TLR3) as studies with MyD88 deficient mice demonstrated a 
significantly attenuated response to ligands of TLR2, TLR4, TLR5, TLR7 and TLR9 (24,25) and 
a member of the IL-1 Receptor subfamily (26,27). MyD88 recruitment upon TLR ligand binding 
subsequently results in recruitment of members of the IL-1R-associated kinase (IRAK) family 
immediately downstream, specifically IRAK4 and IRAK1, which initiate a complex signaling 
cascade involving the specific polyubiquitination of key signaling molecules. A critical 
downstream target of the IRAK kinases is the E3-ligase, Tumor necrosis factor-Receptor-
Associated Factor 6 (TRAF6) which following activation is recruited and undergoes K63 
autoubiquitination. Polyubiquitinated TRAF6 serves as a foundation for the recruitment of 
transforming-growth-factor-b-activated kinase (TAK1) via the ubiquitin-binding adaptors 
TAK1-binding protein 1and 2 (TAB) (28) as well as IKK kinases through binding of the IKKγ 
subunit. Activated TAK1 subsequently leads to activation of the Nuclear Factor-kB kinase (IKK) 
complex and thus NF-kB (described further below) (29-31) as well as the upstream kinases 
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responsible for p38 and JNK activation and specific interferon-regulatory factors (IRFs) leading 
to cytokine and type I interferon production (32). 
The adapter protein TRIF, like other adapter proteins was identified based upon screening 
for TIR-domain-containing proteins (33). TRIF was found to play an important role in both 
TLR3 and TLR4 signaling resulting in IFNB and cytokine production (33-35) and is proposed to 
be the only signaling pathway responsible for induction of apoptosis (36). The importance of 
TRIF is underscored by an abolishment of NF-kB activation or gene up-regulation in response to 
LPS (37) and a loss of cytokine responses to TLR3 ligands with increased sensitivity to viral 
infections (38) in its absence. TRIF serves as the sole adaptor for TLR3 and comprises the 
MyD88-independent signaling arm of TLR4. TRIF signaling cascades utilize many of the same 
downstream effectors as the MyD88 arm to carry out signal propagation. Important exceptions to 
note are the importance of both TRAF3 and RIP1 as being critical to TRIF-mediated NF-kB 
activation in response to TLR3 ligands (39). These signaling cascades are illustrated below in 
Figure 3 for TLR4, which utilizes both MyD88 and TRIF. 
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Figure 3.Adaptor molecule signaling by TLR4. TLR4 is the most complex TLR receptor in that it recruits and 
signals via both MyD88 and TRIF via recruitment of bridging adaptors Mal and TRAM respectively. Both TRIF and 
MyD88 pathways give rise to IKK and subsequently NF-kB activation via TRAF6 activity. TRIF, via activation of 
RIP1 is believed to also lead to pro-apoptotic signaling. TRIF mediated signals also activate IRF3 and IRF7 leading 
to Type I IFN production. MyD88 signaling also leads to activation of MAPK and JNK. FADD (Fas-associated 
death domain), IRF (IFN-regulatory factor), TNF-associated factor (TRAF), TBK (TAK1) Figure reprinted by 
permission of Macmillian Publishers Ltd: Nature Reviews Immunology. Article: (4). Copyright 2012. 
A key downstream target of inflammatory signaling, e.g. PRR-PAMP signaling, is NF-
kB as touched upon briefly above. Expression and activity of NF-kB is present in a large number 
of cell types (40) and serves as an important regulator of a vast number of cellular processes 
including immune function, inflammatory gene expression as well as expression of both pro- and 
anti-apoptotic signals (5,41,42). As a regulator and integrator of such a large number of cellular 
processes, NF-kB activation can occur following an equally diverse set of stimuli not limited to 
microbial antigens or inflammatory cytokines but physical and chemical stresses as well (5). The 
NF-kB transcription factor family is comprised of several members: NF-kB1 (or p50), NF-kB2 
(or p52), RelA (or p65), c-Rel and RelB where Rel designates these members as bearing a Rel 
homology domain at their N terminus. The transcriptionally active NF-kB typically consists of 
p65 and p50 subunits. While homo and heterodimers of the family members can form, typically 
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those not bearing a Rel subunit are not transcriptionally active. NF-kB at resting conditions 
exists as a cytoplasmic complex with IkB proteins, which are inhibitors of NF-kB activity via 
masking of nuclear localization sequences present on the Rel subunits (40). Following activation 
of upstream receptors, e.g. PRRs, IkB specific kinases are activated and are termed IkB kinases 
(IKK). The IKK kinases exist as trimmers consisting of the catalytically active IKKa and IKKb, 
as well as IKKg bearing a regulatory domain (43,44). IKKa catalyzes the phosphorylation IkBa, 
while in complex with NF-kB, which results in targeted polyubiquitination of IkBa and its 
shuttling to the proteasome for degradation (45). NF-kB, now free from the inhibitory complex, 
translocates to the nucleus and initiates transcription of target genes (46) (Figure 4). 
Figure 4.Downstream signals, such as from TLR4, lead to activation of the IKK complex. The catalytically active 
subunits IKKa/IKKb lead to the phosphorylation of the NF-kB inhibitor complex subunit IkBa, subsequently 
tagging it for proteosomal degradation via its ubiquitination and shuttling to the proteasome following its 
dissociation from NF-kB. NF-kB, a heterodimer of RelA-p50, is now free to translocate into the nucleus and binds 
DNA at specific response elements (RE). Specific proteins are subsequently recruited like co-activators and RNA 
Polymerase leading to transcription of target response genes. Figure taken from (47) 
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1.1.3 Toll-­‐like	  Receptor	  4	  
As described previously, TLR4 serves as an important sentinel receptor recognizing a 
number of PAMPs, primarily bacterial endotoxin LPS. TLR4 as well as other TLRs have been 
also demonstrated to recognize specific endogenous ligands released from injured or dying host 
cells. These ligands have been designated as Damage-Associated Molecular Pattern molecules 
(DAMPs) and include host DNA, hyaluronic acid, Heat Shock Proteins (HSPs), and High 
Mobility Group protein B-1 (HMGB1) (Table 1). Signaling in response to DAMPs allows TLRs 
to serve not only as sentinel receptors for invading microbes but as sensors of tissue and cellular 
injury and death; i.e. the presence of “danger signals”(48). 
Table 1.PAMP/DAMP TLR ligands. In addition to recognition of conserved microbial motifs, TLRs also 
recognize molecular motifs of endogenous molecules released following cellular/tissue stress and injury so called 
Damage-Associated Molecular Patterns (DAMPs). Nearly all TLRs have been demonstrated to recognize DAMPs. 
Both TLR2 and TLR4 recognize a wide array of DAMPs including Heat Shock Proteins, heparin sulfate, hyaluronic 
acid and HMGB1. Table reproduced with permission of Remedica. Article: (49). Copyright 2011. 
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In describing the various ligands TLR4 is able to recognize, it is also important to touch 
upon the key accessory proteins that play an important role in TLR4’s ability to bind them. An 
important event in TLR4 signaling in response to LPS is LPS delivery to the receptor itself via 
LPS binding Protein (LBP) (Figure5A). LBP is a acute phase protein with a very high affinity 
for binding LPS (50). LBP-LPS interactions lead to disaggregation of LPS for delivery to CD14, 
an additional accessory molecule important for TLR4 responsiveness. LBPs interactions are not 
limited to LPS or TLR4 as it plays a role in ligand delivery for TLR1, TLR2 and TLR6 (51-53). 
CD14 is a glycoprotein bearing leucine-rich repeats and exists in two forms: a soluble 
form within the blood or a glycosylphosphatidylinositol-anchored membrane protein present 
upon myeloid cells (4). CD14 like LBP plays an important role in signal transduction of a 
number of TLRs derived from its high affinity for a variety of microbial ligands (51,54-57). 
CD14 similar to TLRs exists as a dimer with the ectodomains together forming a structure 
reminiscent of the horse-shoe like solenoid structure of the TLRs with a hydrophobic pocket key 
for ligand (LPS) binding (58). Interestingly in response to LPS, CD14 is required for TRIF-
dependent signaling and at MyD88-dependent signaling at low doses of LPS (59,60). CD14 has 
also been implicated in the chaperoning of LPS from LBP to TLR4 at the cell surface. Recent 
evidence also suggests CD14 plays a key role in the LPS induced endocytosis of TLR4 into early 
endosomes where the signaling complex can engage TRIF-dependent signaling (60-63) (Figure 
5B). 
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Figure 5.TLR4-LPS binding complex and TLR4 endocytosis. A. Lipopolysaccharide (LPS) recognition by TLR4 
is heavily dependent upon several upstream accessory proteins. The acute phase protein LPS-binding protein (LBP) 
efficiently binds LPS within the extracellular space and delivers it to CD14. CD14 is anchored to the plasma 
membrane via GPI links. MD2 is critical for the homodimerization of TLR4 and creates a LPS binding pocket 
critical for the binding and recognition of LPS by TLR4. B. Upon LPS binding the CD14-MD2-TLR4 complex a 
host of adaptor molecules are recruited to the TIR-domain of TLR4. MAL(TIRAP) serves as a bridging adaptor 
recruiting MyD88 giving rise to TRAF6 and IRAK4 activation and subsequently NF-kB activation. The accessory 
protein TRAM functions to sort TLR4 to the early endosome followed by its subsequent recruitment of TRIF to the 
TIR-domain. TRIF-mediated NF-kB activation occurs via TRAF6 and RIP1 dependent activation of the IKK 
complex. IRF3 activity occurs via TRAF3 mediated signal transduction. Figure reprinted with permission of 
Macmillian Publishers Ltd:Nature Reviews Immunology. Article:(4). Copyright 2012. Figure reprinted with 
permission of Elsevier. Article (64) 
Another important accessory molecule is MD2, a glycolsylated soluble protein that 
associates with the extracellular domain of TLR4 that is fundamental to TLR4 expression on the 
cell surface (65,66). Recent crystal structures of the TLR4-MD2 complex demonstrate that LPS 
inserts 5-6 of its lipid chains within the hydrophobic pocket of MD2 (67). Interestingly, of the 
TLR-Ligand crystal structures that have been resolved, TLR4 is the only one requiring accessory 
molecules for ligand binding (68). Presumably this is due to the little direct interaction the two 
TLR4 molecules make within the dimer itself making MD2 required not only for ligand binding 
but TLR4 dimerization (67). 
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1.1.4 Innate	  Immunity	  in	  the	  Small	  Intestine	  
The small intestine is the organ critically responsible for the absorption by the host of 
essential nutrients. While performing this fundamental function the small bowel must also 
maintain a strict barrier and mount effective and contained immune responses to defend against 
pathogenic microbes and maintain homeostasis with commensal flora. The gut represents a 
dynamic immunological system where the presence of commensal flora and exposure to external  
antigens from ingested sources. The gut immune system must be robustly activated but tightly 
and delicately controlled. Disruptions in the activation or the regulatory mechanisms governing 
gut immune homeostasis unsurprisingly can give way to a host of gastrointestinal pathologies. 
The immune system within the small bowel can be divided into two distinct sections: the outer 
epithelial layer and the inner lamina propria (Figure 6). The principle component of the outer 
section is a single layer of Intestinal Epithelial Cells (IECs) which differentiate into four distinct 
cell types: absorptive enterocytes, enteroendocrine cells, mucus-secreting goblet cells and 
antimicrobial-secreting Paneth cells; all derived from a common stem cell progenitor located 
within the crypts of each villus critically dependent upon Notch-mediated epithelial 
differentiation (69,70). Interspersed between the IECs are Intraepithelial Lymphocytes (IELs) 
along with dendritic cell extensions. DC extensions, IELs and M cells present in this layer play 
an important role in first-line defense as partaking in luminal antigen sampling. The lamina 
propria contains the body of the DCs, neutrophils, macrophages, IgA-producing plasma cells, 
NK, T and T-reg cells. This inner section of the intestinal immune system is known collectively 
as the gut-associated lymphoid tissue (GALT), which includes Peyer patches, isolated lymphoid 




Figure 6.Structural and cellular features of the intestinal mucosa. A. Fixed section of the small bowel from a 
C57bl/6 mouse stained for various structural and cell-specific proteins. Ecadherin (red) and Dapi stains delineate 
villus structure and cell nuclei respectively. CD3 staining (green) detects Tcells within the epithelial monolayer, 
Intraepithelial lymphocytes (IELs) or within the lamina propria (LPL). Highly secretory cells within the epithelium: 
the Paneth and Goblet cells are depicted via wheat germ agglutinin stain (WGA). Paneth cells exist within the crypts 
intercalated between stem cells (not depicted). Goblet cells exist within the epithelial monolayer higher up on the 
crypt-villus axis. B. A cartoon representation of A clearly illustrating the intestinal milieu and localization of 
epithelial cell types as well as intestinal immune cells including macrophages, T cells and IgA producing B cells. 
Intestinal APCs, dendritic cells with luminal sampling extensions and M cells are also depicted. Together these cells 
and their secreted factors including mucus and anti-microbial peptides, maintain gut-immune homeostasis in the face 
of the ever-present commensal flora. Figure reprinted by permission of Macmillian Publishers Ltd: EMBO Reports. 
Article: (19). Copyright 2012 and Nature Reviews Immunology. Article: (71). Copyright 2012 
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A predominant secreted product within the intestine is IgA from the plasma cells, which 
is important for the prevention of microbes from traversing the intestinal barrier as well as their 
clearance and activation of effector immune cells (72,73). An additional highly produced and 
secreted product within the intestine is mucus. Mucins are large glycoproteins produced by 
goblet cells that are secreted to provide a physical barrier and can facilitate removal of bacteria 
and decreasing bacterial loads via binding and clearance via peristalsis (74). A host of mucin 
genes lead to the production of proteins that are anchored to the cell membrane while the most 
abundant produced form, derived from the MUC2 gene, is packaged into storage granules and 
secreted into the lumen (75). MUC2-encoded mucus secretion occurs at baseline but has also 
been demonstrated to increase upon inflammatory stimuli to aid in microbial clearance (76,77). 
Mucus also maintains the ability to capture and hold signaling molecules and can play a key role 
in signaling processes promoting wound healing, decreasing apoptosis and regulating 
inflammatory responses (78-80). Recent work also has implicated goblet cells as contributing to 
the delivery of luminal antigens to antigen-presenting cells residing in the lamina propria (81). 
In addition to the mucus layer, the epithelial layer itself serves as a physical immune 
barrier through a system of junctional proteins act as both gatekeepers of transcellular transport 
and “spot-welds” and fortifications between epithelial cells to invading microbes. These 
junctional proteins are grouped into tight junctions (TJ), which serve to bind cells together at the 
apical surface, and adherens junctions (AJ) which bind cells at their lateral surfaces. TJs include 
Occuldins, Claudins, and junctional Adhesion Molecules (JAMs). Each of these proteins plays 
an important regulatory role in porosity of the epithelial layer and the macro/micromolecule 
absorbance (82). Loss of function of any of the TJs can lead to altered cellular polarity and 
permeability (83). AJs also are important sites of intracellular signaling and loss of these 
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connections not only can disrupt cellular polarization but can lead to apoptosis (84). 
Alongside mucins and IgA, the gut, chiefly via the Paneth cells, also actively secretes a 
host of anti-microbial peptides aimed at curbing bacterial load and maintaining gut homeostasis 
(85). Paneth cells, located within the crypt base, maintain and release granules containing a 
number of AMPs including lysozyme, α-defensins, TNFα, anti-microbial lectins known as 
RegIIIα (RegIIIγ in mice) (86-88). Typically secreted AMPs remain local within the crypt acting 
to safe-guard the precious stem cell progenitors, but under inflammatory stimuli have been 
demonstrated to be secreted to support immune responses and defenses of the epithelial layer as 
well adding to the antimicrobial activity of epithelial secreted AMPs including β-defensins and 
RegIIIα/γ (88,89). 
An integral part of the intestinal immune system is the presence of previously described 
PRRs in the intestinal epithelium. In the human intestine epithelium, TLR1 to 5 and TLR9 have 
been detected and serve as sentinels for PAMPs and DAMPs (90). PRR expression by IECs is 
fundamental to maintain intestinal homeostasis, discerning between pathogenic and commensal 
bacteria. PRR signaling within the epithelium is important for stimulating the protective factors 
mentioned above as well as immune signals including cytokines such as thymic stromal 
lymphopoietin (TSLP) important for T cell maturation, chemokines and growth factors. The 
important factors for maintaining microbial homeostasis are summarized in Figure 7.  
With the presence of commensal bacteria within the intestinal lumen, given what is 
known of PRR-PAMP signaling, indiscriminate PAMP recognition would be expected to yield a 
significant inflammatory response. However, this is known to not occur and in fact the 
epithelium seems to tolerate the presence of these PAMPs and actually depends on the presence 
of these signals for normal function and sensing when breaches by pathogenic microbes occurs 
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(71). To underscore the importance of tonic innate immune signals in maintaining gut 
homeostasis, epithelial-specific deficiencies of IKKγ, IKKα/β, TAK1 and p65 in addition to 
expression of a dominant-negative form of MyD88 leads to spontaneous barrier dysfunction and 
subsequent mucosal injury and inflammation (91-94).  
Figure 7.Role of the intestinal epithelium in maintaining gut immune homeostasis. Host immune protective effects 
are illustrated in blue and include IgA secretion via plasma cells and several cytokines and chemokines released 
from immune cells residing in both the lamina propria and within the epithelial monolayer. Epithelial effects are 
demonstrated in orange and include barrier maintenance via mucus production and secretion of antimicrobial 
peptides from IECs and Paneth cells. IECs also play a key role in communication with the underlying immune cells 
via release of important immune signaling proteins including macrophage inflammatory protein 2 (Mip2) and 
thymic stromal lymophoietin(TSLP). Depicted in red are various microbial ligands i.e. PAMPs that provide 
important homeostatic signals but if unchecked can lead to significant intestinal inflammation and injury. Figure 
reprinted by permission of Macmillian Publishers Ltd: EMBO Reports. Article:(19). Copyright 2012 
One contributing factor to ensuring balance between mucosal immunity and commensal 
flora is receptor compartmentalization. The apical surface is frequently exposed to commensal 
flora while the basolateral side, in physiologic conditions is relatively protected from such 
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encounters. Under physiological conditions different PRRs are varyingly expressed both in level 
and spatially when comparing large versus small bowel which may be driven, in part, by density 
of microbial flora (19,71). A prime example of how PRR compartmentalization contributes to 
maintenance of mucosal immune homeostasis and discriminate targeting of pathogenic versus 
commensal flora is evident in TLR5 and TLR9 localization. IEC TLR5 expression is restricted to 
the basolateral side of human colonic epithelium and was found to only respond to flagellin in ex 
vivo murine colonic cultures following epithelial barrier disruption (95,96). TLR9, however, is 
present on both the apical and basolateral membranes (97), but, impressively, initiates different 
signaling cascades depending in which compartment ligand binding occurs. Apical signals are 
translated into epithelial-commensal “tolerogenic” and anti-inflammatory signals where 
interpretation of basolateral signals results in significant pro-inflammatory signals (98). Similarly 
receptor compartmentalization is also effective at limiting and tailoring responses to released 
endogenous immune mediators. For example, IEC responses in vivo to type III IFNs produced 
following viral infection are robust while responses to type I IFNs are not, despite expression of 
both receptors. This is presumably due to type I IFN receptors localized to apical surfaces (99). 
Of note, comparison of PRR localization between “professional” immune cells and IECs is also 
suggestive of significant differences in the PRR-PAMP responses between these cells e.g. TLR9 
“tolerogenic” signals in IECs vs pro-inflammatory signals in macrophages.  PRRs have been 
demonstrated to undergo significant up-regulation and relocalization following stimulation (71) 
especially in regards to TLR2 and TLR4 (16,100). In the small intestine, epithelial expression of 
TLR4 is primarily restricted to an intracellular compartment (101-103). Therefore TLR4 
stimulation requires ligand internalization facilitating a sustained epithelial response similar to 
intracellular-restricted TLR9 signaling and responses in macrophages (104).  
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Another mechanism ensuring immune responses remain in a steady-state balance despite 
tonic contact with commensal bacteria and bacterial products arises from a set of proteins 
specifically charged with limiting PRR signaling. One such protein is Toll-interacting protein 
(TOLLIP) that inhibits TLR2 and TLR4 signaling. TOLLIP directly associates with both TLR2 
and TLR4 and leads to a decrease in IRAK phosphorylation and activity and also serves as a 
substrate for IRAK activity, with no affect upon IRAK recruitment (105,106). TOLLIP functions 
as a negative regulator of TLR signaling in IECs through up-regulation following LPS or 
lipotechoic acid treatment (107). A critical role for TOLLIP has also been identified in patients 
with inflammatory bowel disease where IECs isolated from these patients demonstrated a 
significantly reduced ability to up-regulate TOLLIP expression (108). A highly expressed 
regulator of TLR signaling in IECs, along with IL-1R and IL-33R is single immunoglobulin IL-
1R-related molecule (SIGIRR) (109). Impaired up-regulation of SIGIRR expression, like 
TOLLIP, leads to exacerbation of intestinal inflammation (110,111). SIGIRR is characterized by 
a single extracellular Ig domain and a TIR domain that are required for its inhibitory activity 
which includes trapping of TRAF6 and IRAK1 (109). An additional regulator of TLR signaling 
is a member of the IRAK family, which is specifically comprised of two active kinases (IRAK 
and IRAK4) and two inactive kinases (IRAK2 and IRAK-M). IRAK-M serves as a negative 
regulator of TLR signaling, initially believed to be restricted to macrophages (112). However, it 
is also present and functionally active in IECs (113). IRAK-M is up-regulated following LPS 
signaling in macrophages and subsequently induces LPS tolerance. IRAK-M prevents formation 
of IRAK-TRAF6 complex formation indirectly via substantially increasing the affinity of both 
phosphorylated and unphosphorylated IRAK4 for MyD88 preventing the disassociation of the 
early TLR signaling complex and TLR signal propagation (112). Key events in TLR signaling 
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and NF-kB activation cascades involve the polyubiquitination of specific target protein. 
Therefore, deubiquitination of these targets by deubiquitinases (DUBs) serve as a central 
regulatory crossroad. One of the most important DUBs regulating NF-kB activation is A20 
(114,115). Multiple NF-kB activating stimuli were found to induce A20 expression (116,117) 
and A20 overexpression inhibited this activation (118,119). A20 functions to catalyze the 
deubiquitination and inactivation of TRAF6 (120). The importance of A20-mediated negative 
feedback is underscored by the fact that mice lacking A20 died prematurely due to spontaneous 
multi-organ inflammation and displayed a significant inability to curb inflammatory responses 
even when exposed to sub-lethal doses of LPS (121). 
The epithelial monolayer exists as a simple sheet composed of numerous IECs that 
maintain the ability to communicate with its horizontal neighbors via intracellular connections 
known as Gap junctions (122-125). These connections have proved vital to a variety of tissue 
processes including electrical coupling and neuronal synapses (126) and serve as important 
cellular communication relays among IECs in coordinating immune responses. IECs forward 
immune responses horizontally via the generation and diffusion of messenger molecules, such as 
Reactive Oxygen Species (ROS), through gap junctions into neighboring cells (127,128). PRR-
PAMP/DAMP signals also promote gap junction communication via up-regulation of a group of 
proteins that compose gap junctions named connexins (129). Aside from gap junctions cytokine 
secretion functioning in an autocrine manner also serves to foreword inflammatory signals to 
neighboring epithelia (130,131) (Figure 8). 
Thus, the presence and activation of PRRs is not only important for immune responses 
but for key intestinal processes including IEC proliferation (19,71), TJ maintenance (132), AMP 
expression (19) and intestinal wound healing (133). Despite the many beneficial functions of 
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TLR4 signaling within the intestinal epithelium, a number of diseases have been associated with 
exaggerated TLR4 expression and signaling including Uleratvive Colitis, Crohn’s disease, 
intestinal malignancies and Necrotizing Enterocolitis (71,134). 
Figure 8.Innate immune signaling of the IEC. PRRs (TLRs, NLRs and RLRs) recognize microbial motifs from 
both pathogenic and commensal microbes. PRR signals give rise to IKK activation and NF-kB (RelA) activation and 
subsequent cytokine/chemokine and anti-microbial peptide production. NF-kB responses also lead to activation of 
proliferative, differentiation and survival signals. Increased Gap junction proteins maintain key intracellular 
channels for conducting signals (e.g. cytokines, ROS) to neighboring IECs and IELs. PRR signals also lead to 
inflammasome activation leading to production of active IL-1b and IL-18. Negative regulators of PRR signaling 
ensure intestinal inflammatory responses do not occur unchecked and remain tightly titrated. SIGIRR, A20 and 
PPARγ are among the fundamental PRR regulators important to immune homeostasis and attenuation of 
inflammatory signaling following clearance of invading microbes. Figure reprinted by permission of Macmillian 
Publishers Ltd: EMBO Reports. Article: (19). Copyright 2012 
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1.2 NEONATES:	  PRETERM	  VS	  TERM	  
With the increase in the number of induced vaginal deliveries and elective cesarean 
sections, the number of preterm births, defined as <37 weeks, has significantly increased (42). As 
medical facilities become more advanced, there has been a significant improvement in the 
survival rate of these preterm infants. However, this is not without its complications, one of 
which includes severe gastrointestinal disorders, and Necrotizing Enterocolitis (NEC) is the most 
significant. The preterm infant demonstrates various signs of organ immaturity resulting in a 
maladaptation to postnatal life. The gastrointestinal tract is among the most stressed organs in the 
preterm infant as it is ischemic, developmentally immature, unable to adequately meet the 
nutrient demand of the infant and rapidly colonized with commensal flora much earlier than 
anticipated. Compared with the intestinal tract of the term infant, the preterm infant displays 
deficiencies in structural integrity of the gut barrier, global and gut-specific immune function and 
dysregulated blood flow predisposing the gut to ischemia. These factors, as well as the onset of 
enteral feeds in these infants, represent major pathogenic factors for the development of NEC. 
1.2.1 Amniotic	  fluid	  
The human fetus while in utero is bathed in amniotic fluid (AF) and estimated to swallow 
100-200ml per kilogram body weight per day (29), which constitute a significant nutrient and 
energy source for the fetus (30). AF plays an important role in normal gut development, through 
the presence of many beneficial factors present such as epidermal growth factor (EGF) and 
insulin-like growth factor (IGF-1). These factors stimulate tissue and enterocyte growth in utero 
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and aid in nutrition uptake postnatally (31). In addition, AF plays an important 
immunomodulatory role via the presence of IL-10 (71) and TGF-β (72). Contained within AF are 
also anti-microbial peptides such as defensins and lysozymes conferring protection against 
bacterial infection (73). The preterm infant however is at a significant disadvantage as its 
exposure to AF is significantly decreased compared with the term infant, predisposing it to 
gastrointestinal disorders. Indeed, the key protective effects of orally administered AF have been 
demonstrated to limit NEC development in both mice (117) and pig (135) models of this disease 
through reduction in both intestinal inflammation and apoptosis. These studies demonstrate that 
the bioactive properties of AF in utero, among them EGF, may positively affect the immediate 
postnatal development of the intestine in preterm infants as well. There is a considerable 
functional overlap between the prenatal effects of AF and the postnatal effects of breast milk, 
which contains very similar biologically active factors to those contained within AF. It appears 
that AF possibly functions to prepare the gut for the dramatic shift between the in utero 
environment and that immediately following birth.  
1.2.2 Breast	  Milk	  
There is a growing body of evidence (42) that breast milk is far superior to infant formula 
in stimulating the maturation of the gut, which is especially important in the preterm infant 
where digestive and absorptive functions are quite immature. Factors present within the breast 
milk and absent in formula are believed to mediate the beneficial intestinal effects of breast milk 
in the neonate. These factors are biologically active within the gut as they are quite resistant to 
proteolytic degradation. Growth factors present in breast milk such as EGF and IGF-1 have been 
shown to stimulate gut growth and maturation in terms of increasing intestinal barrier integrity, 
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villus height and brush-border digestive enzyme expression (75). Along with macronutrients, 
breast milk also provides important immunoprotective properties during the critical post-natal 
period underscored by the increased occurrence of infection and gastrointestinal disease in 
preterm infants fed formula (77,78). Among the protective immunological factors conferred via 
breast milk are immunoglobulins, lymphocytes and macrophages (79). These factors not only 
provide direct protection against infection, but also serve as important stimulators of the 
currently immature newborn immune system. They also provide fundamental tolerance signals 
critical for the maintenance of gut immune homeostasis in the face of both harmful and harmless 
antigens. Failure of tolerance signals are believed to be major contributing factors to the 
development of food allergies, autoimmunity as well as inflammatory bowel disorders 
(80,82,83). Similar to their significantly attenuated exposure to AF, preterm infants are also 
significantly deprived of breast milk and fed primarily through total parenteral nutrition and/or 
infant formula. It remains a critical area of research to identify key factors within breast milk that 
are “NEC-protective”. Recent studies have identified key components of breast milk such as 
Erythropoietin (136) to significantly protect against models of NEC.  
1.2.3 The	  Immune	  System	  of	  the	  Newborn	  Intestine	  
Bacterial colonization of the intestine is a key step in the development and maturation not 
only for the gut immune system but for remote organs as well. Critical lines of defense against 
both pathogenic and commensal flora are the physical and chemical barriers aimed at microbial 
clearance mentioned in the previous section including: peristalsis, AMP release, barrier integrity, 
and mucus layers. However, in the preterm gut these critical defense mechanisms are 
significantly under-developed. Microbes that cross this first-line of defense will activate immune 
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responses in both the innate and adaptive arms aimed at clearing the invader. The immune 
system development begins early in the embryonic period but continues to mature up to about 1-
2 years of age (137) depicted schematically for both the innate and adaptive arms in Table 2.  
Table 2.Timing of acquisition of mature immune function in the human. Preterm infants, most at risk of 
developing NEC, are afflicted by disorders of prematurity such as generalized hypoxia due to immature lung 
development. Not surprisingly preterm infants have a significantly immature innate and adaptive immune system. 
Intestinal barriers in these infants are also underdeveloped. These factors make preterm infants far more susceptible 
to acquiring infections and uncontrolled and undirected immune responses following colonization. Table 
repreoduced with permission from Pediatrics article (136) by the AAP. Copyright 2010 
This therefore results in an “immunocompromised” neonate at birth, whose proper 
development is dependent upon both AF prenatally and breast milk postnatally. The immature 
physical and chemical barriers, limited functions of key immune effector cells and proteins, 
which characterize the preterm infant, unsurprisingly predispose them to diseases. To highlight a 
few adaptive arm deficits, the preterm neonate displays: T-cell deficiencies (T-helper 2 skewed 
cytokine responses, increased T-reg populations and decreased CD8 T-cell cytolytic activity), 
weak B-cell activity (dampened Ig production especially in response to polysaccharide antigens, 
poor T-cell-mediated B cell activation) and underdeveloped secondary lymphoid tissues 
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(138,139). Both adaptive and innate immunological deficits in the preterm infant compared with 
the term neonate are summarized in Table 3. 
Table 3. Specific immunological deficits in both the adaptive and innate arms of the preterm infant compared with 
the term infant. Table reprinted with perimission from Elsevier. Article: (42). Copyright 2011. 
In Figure 9 key differences between the milieu of the preterm and term infant are 
depicted illustrating that the preterm infant is significantly at risk for development of 
gastrointestinal diseases such as NEC. The preterm gut therefore represents a “perfect storm” of 
maladaption to the outside environment with deficits of physiologic digestive/absorptive gut 
functions as well as incoordination of immune signals and responses. 
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Figure 9. Intestinal milieu: Term vs. Preterm. Compared to the term neonate (top), preterm infants (bottom) 
demonstrate significantly reduced digestive and absorptive capacity, impaired barrier integrity, blood flow and 
dysfunctional mucosal immunity. The preterm gut barrier is compromised due to increased IEC apoptosis, decreased 
AMP and IgA production as well as decreased TJ and mucus expression. A dysregulation of gut immunity gives rise 
to exaggerated immune responses to both translocating pathogenic and commensal flora. IEC injury and controlled 
inflammation further facilitate bacterial translocation yielding a vicious cycle typically culminating in the 
development of NEC. Figure reprinted with permission from Elsevier. Article: (42). Copyright 2011. 
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1.3 NECROTIZING	  ENTEROCOLITIS	  
Necrotizing Enterocolitis (NEC) is the leading cause of death for gastrointestinal disease 
in neonates, and remains a major cause of morbidity in those who survive this devastating 
disease (140,141). NEC occurs in approximately 1 to 3 per 1000 live births and accounts for 
nearly up to 10 percent of all neonatal intensive care unit admissions (142). The excessive and 
extensive intestinal inflammation and injury characteristic of NEC leads to mucosal ulceration 
and frank necrosis (Figure 10) of intestinal tissue along with disruption of the intestinal barrier. 
This subsequently can extend systemically leading to multisystem organ failure as well as 
significant brain injury and can lead to significant developmental delay in those infants who 
survive. Despite the marked improvements in overall neonatal care in general, the management 
approach to the infant with NEC has not changed in the past 30 years, and the outcome is 
generally as poor today as it was 3 decades ago (143). Based on these sobering statistics, it is 
clear that new therapeutic approaches to NEC are required and that such approaches will demand 
a greater understanding of the molecular mechanisms that contribute to the development of this 
disease. As was recently summarized by the 2006 NICHD workshop on NEC research, “NEC 
can be thought to arise from an uncontrolled exuberant inflammatory response to bacterial 
colonization that characterizes the intestine of premature infant” (144). In the management of 
this disease there is no specific treatment that exists –primary support is focused upon 
maintenance of hemodynamic parameters and administration of broad-spectrum antibiotics. In 
severe cases surgical resection of afflicted bowel is required leading in many cases that are 
associated with morbidity, such as short gut syndrome. This is underscored by the inability to 
acquire adequate nutrition with overall surgical survival remaining at 50% (145). Due to the fact 
that since its initial description in 1965 (143) little progress has been made in improving the 
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overall survival, there remains a profound interest from individuals involved in the care of 
preterm infants and research community to develop a cure or adequate preventive strategy for 
NEC. Several investigators have now examined the mechanisms that mediate the signaling 
response of the newborn intestine to bacteria and have detailed the consequences of this 
signaling response to the pathogenesis of NEC. In particular, these studies have uncovered an 
essential role for a class of bacterial receptors named Toll-like receptors (TLRs) in the 
pathogenesis of NEC and have provided compelling evidence to suggest that blunting the ability 
of TLRs to signal within the intestinal epithelium of the newborn infant may either prevent or 
treat NEC. These findings place the spotlight on the molecular basis that underlies the interaction 
between the intestinal epithelium and the commensal microbial flora. These studies also suggest 
that the ability of TLRs to respond to bacteria within the newborn intestinal epithelium may, in 
part, explain the particular susceptibility of the premature infant to the development of NEC. The 
following subsections will delve deeper into the role of TLR4 in the pathogenesis of NEC as well 
as recent advances in the elucidation of the pathogenesis and therapeutic targets for this disorder. 
Figure 10.Gross image of frank necrotic bowel at time of bowel resection in a preterm infant afflicted by NEC. 
Figure taken from(146) 
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1.3.1 An	  Essential	  Role	  for	  TLR4	  in	  the	  Pathogenesis	  of	  Necrotizing	  Enterocolitis	  
A role for LPS—and by extension for TLR4—in the pathogenesis of NEC is 
highlighted by the findings that LPS administration in association with systemic stress induces 
NEC in animals (147-149). Based on the observation that NEC is known to develop after the 
intestine has been colonized with Gram-negative bacteria, serum levels of LPS are increased in 
patients with both NEC and inflammatory bowel disease, a disorder that shares histopathological 
features with NEC (150-153), and levels of LPS are significantly increased in the plasma and 
stools of infants and mice that develop NEC compared with healthy counterparts (154,155), 
several laboratories have sought to establish whether TLR4 may play a role in the pathogenesis 
of this disease. The Caplan laboratory showed in 2006 that mice with mutations in TLR4 are 
protected from the development of NEC (156). The Hackam laboratory in 2007 confirmed that 
mice lacking TLR4 do not develop NEC and extended these observations by demonstrating that 
TLR4 signaling regulates the balance between injury and repair in the newborn intestine (155). 
Several laboratories have shown that TLR4 is increased in the intestinal mucosa of mice, rats, 
and humans with NEC compared with controls (155,157) and that activation of enterocyte TLR4 
leads to an increase in death of the cells that line the intestine through the process of apoptosis 
(158). Along with the increase in epithelial death that accompanies TLR4 activation in the 
newborn small intestine, TLR4 activation within the intestine was also found to reduce the 
capacity of mucosal healing to occur because of a reduction in enterocyte proliferation (159) and 
reduced enterocyte migration (160). Taken together, these findings demonstrate that TLR4 
activation in the newborn small intestine leads to the development of NEC through profound and 
deleterious effects on promoting intestinal injury and reducing the capacity for mucosal repair. 
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Other authors have shed light on additional roles played by TLR4 in the pathogenesis of NEC. 
Luk and coworkers (157) have shown that the activity of the TLR4 signaling pathway was up-
regulated in intestinal tissues from premature neonates and rats with NEC compared with 
controls. This concept is supported by the work of Liu et al. (161) who reported that TLR4 
expression and signaling is increased in the intestine of rats with NEC when compared with 
control rats, and that such increases precede histological evidence of mucosal injury in this 
disease. Further evidence of the physiological relevance of these findings is demonstrated by Lu 
et al. (162), who showed that while TLR4 expression is increased in the intestinal mucosa of rats 
with NEC, agents known to reduce NEC may protect from the development of NEC through a 
reduction in TLR4 expression. Wolfs et al.(163) have shown that the absence of the key TLR4 
regulatory molecule MD-2 in the immature infant bowel may lead to impaired bacterial sensing 
and thus predispose to NEC on microbial colonization of the premature intestine via disruptions 
of gut immune homeostasis.  
1.3.2 TLR4	  Modulation	  of	  Intestinal	  Barrier	  Integrity	  and	  Bacterial	  Translocation	  
The integrity of the intestinal barrier is paramount to preventing frank translocation of 
bacteria as well as PAMPs into the systemic circulation. Increases in the concentration of 
circulating LPS and bacterial species characterizes infants with NEC and greatly increases the 
likelihood for these patients to progress to systemic sepsis and organ failure. Increases in the 
concentration of circulating LPS and TLR4 expression as seen in NEC exert significant 
deleterious effects upon the integrity of the intestinal barrier. Increased NO production due to 
increased activity of iNOS has been demonstrated in settings of gut inflammatory 
states(164)including in response to LPS (165). Through the utilization of iNOS mutant animals, 
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LPS-induced intestinal injury, barrier dysfunction and bacterial translocation were found to be, in 
part (166), iNOS dependent (167-170). LPS-induced barrier disruption via NO generation by the 
enterocytes themselves (171). NO donors have been demonstrated to lead to increased bacterial 
translocation via enterocyte damage directly as well as tight junction dilatation (172) and 
inducing bacterial internalization (173). Exaggerated LPS-TLR4 signaling has also been 
demonstrated to lead to TJ and AJ disruption and down-regulation directly (174,175). Enterocyte 
TLR4 was also shown, by the Hackam laboratory, to lead directly to translocation of bacteria via 
TLR4-mediated internalization of Gram-negative bacteria into membrane-bound phagosomes. 
Furthermore, TLR4 signaling was found to be critical and sufficient for enterocyte phagocytosis 
as LPS-coated latex particles were preferentially internalized compared with uncoated controls. 
Additionally, HEK-293 cells, which do not express TLR4, acquired the ability to internalize E. 
coli once transfected with TLR4-MD2 compared with untransfected controls. Internalization of 
Gram-negative bacteria across the epithelium to mesenteric lymph nodes was demonstrated to be 
significantly decreased in TLR4-mutant animals compared with wild-type counterparts (103). 
1.3.3 TLR4	  Inhibition	  of	  Intestinal	  Restitution	  
The intestinal epithelial monolayer is subjected to a variety of physiologic stressors and 
subsequently undergoes complete epithelial turnover every 3-5 days (176).  In order for this to 
occur with little to no lag in intestinal function and barrier integrity, the epithelial monolayer 
must possess robust regenerative capacity. Following epithelial injury or physiological 
sloughing, IECs within the epithelial monolayer will be lost, posing a potentially critical problem 
of gut barrier maintenance. Gaps within the monolayer are filled through two coordinated 
processes: Epithelial Restitution and Proliferation. Restitution involves migration of surrounding 
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IECs to close the gap rapidly. Subsequent generation of new IECs from both intestinal stem cells 
and surrounding epithelium completely restores and closes the monolayer defect (41). In seeking 
to explore the mechanisms by which TLR4 adversely affects mucosal repair, TLR4 activation 
was observed to increase the adhesiveness that enterocytes exert on their underlying matrix, 
profoundly restricting their ability to move along the basement membrane via increased TLR4-
mediated activity of Rho-GTPase and focal adhesion kinase and focal adhesion generation. 
These adhesions culminated in a significantly reduced migration rate of cultured IECs following 
wound generation of a confluent epithelial monolayer as well as in vivo as demonstrated via 
decreased migration of BrdU labeled IECs following intraperitoneal injection of LPS and 
subjection to NEC model (105,155,177). The activation of Rho-GTPases culminating in 
decreased IEC migration was demonstrated to occur upon NO generation via TLR4 stimulation 
(178). 
In addition to significant reductions in enterocyte restitution TLR4 signaling concurrently 
inhibits IEC proliferation, in the small bowel, upon exposure to LPS injection and NEC models 
(155). TLR4 activation inhibits enterocyte proliferation through direct dysregulation of the wnt-
β-catenin signaling pathway, which is the predominant signaling cascade that regulates cell 
division within the intestine (159). It is also important to emphasize that TLR4 activation in 
enterocytes —as opposed to other TLR4-expressing cells such as macrophages—was found to be 
important in the pathogenesis of experimental NEC, as the delivery of viral particles expressing a 
dominant negative form of TLR4 to the intestinal epithelium of mice reduced NEC severity 
(159) as well as through the generation and use of mice lacking TLR4 expression specifically in 
the intestinal epithelium via CRE-LOXP technology (70). 
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1.3.4 TLR4	  Induction	  of	  Enterocyte	  Apoptosis	  
One of the most critical aspects of the pathogenesis of NEC remains IEC apoptosis. 
Apoptosis refers to a type of cellular death that is programmed and well coordinated with a set of 
standard morphological features culminating in the removal of dying cells (179) (Figure 11). 
Unlike necrosis, which is a form of cell death that incorporates rapid breakdown of cellular 
membranes and release of pro-inflammatory cellular contents, such as DAMPs, into the 
extracellular space (180) apoptosis is typically non-inflammatory. Triggers of enterocyte 
necrosis in the gut include trauma (ischemia-reperfusion) and bacterial toxins (181). Necrosis 
and apoptosis differ also in regards to their respective etiologies where necrosis is due to 
pathogenic means and apoptosis can be physiologic or pathologic. Indeed, enterocyte apoptosis 
is quite necessary to allow for epithelial turnover and maintenance of monolayer integrity (41). 
The decision for a specific cell to begin the programmed cell death cascade is one that 
represents a very delicate and intricate balance of pro- and anti- apoptotic signals.  In mammalian 
cells, the decision to initiate apoptosis signaling cascades is heavily influenced by the activation 
and activity of a family of cysteine proteases named Caspases. The activation of these proteases, 
which exist within cells as inactive precursors, can occur via two distinct pathways: The intrinsic 
and extrinsic pathways (183) (Figure 12). Classical activators of the extrinsic pathway includes 
Tumor Necrosis Factor-a (TNFα), Fas Ligand and a host of TLR ligands including LPS 
(180,184-187). Binding to their respective receptors leads to a pro-apoptotic signal that yields the 
recruitment of Fas-Associated Death Domain (FADD) or MyD88, in the case of TLR4, to the 
death domain of the receptor thereby leading to formation of the Death-Inducing Signaling 
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Complex (DISC) upon complex formation with and activation, via proteolytic cleavage, of pro-
caspase 8 (188). Once Caspase 8 has been released from the DISC in its active form, it will next 
Figure 11.Basic cellular morphology and processes of apoptosis. Following initiation of apoptosis via a variety of 
stresses, biochemical events are put into play that lead to characteristic morphological changes and cell death. 
Changes include rapid chromatin/nuclear condensation into compact patches alongside the nuclear envelope 
(pyknosis) and chromatin/nuclear fragmentation (karyorrhexia). The nuclear envelope becomes discontinuous. Cells 
undergo significant shrinkage and rounding with generalized blebbing of the plasma membrane. Cells subsequently 
break apart into several vesicles termed apoptotic bodies containing condensed cytoplasm and tightly packed 
organelles which are quickly cleared via surrounding phagocytic cells. The rapid packaging and clearance of 
apoptotic bodies ensures, unlike in necrotic death, dying cells do not elicit an inflammatory response. Figure taken 
from(182) 
continue on to activate downstream caspases including caspase 3 and 7 in addition to BH3-
interacting domain death agonist (BID). This culminates in an increase in mitochondrial 
outermembrane permeability and cell death (189). Increased permeability is achieved via pro-
apoptotic proteins including Bcl-2 associated X (BAX) and Bcl-2 antagonist/killer (BAK) which 
are mitochondrial membrane bound and lead to pore formation, the mitochondrial apoptosis-
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channel, upon their activation (190). This thereby causes the release of both Cytochrome c as 
well as the Second mitochondrial activator of caspases (Smac) (190,191). Upon its release, 
Cytochrome c is free, along with apoptotic protease-activating factor (APAF1) and procaspase 9, 
form the Apoptosome. The apoptosome then functions to activate procaspase 9 releasing caspase 
9, which in turn cleaves and activates procaspase 3 (180,192). Release of Smac serves to prevent 
inhibitors-of-apoptosis proteins (IAP) from blocking the function of the apoptosome (189,190). 
Once activated, caspase 3 proceeds to target specific proteins which include the inhibitor of 
caspase-activated DNase (ICAD), which thus frees CAD to enter the nucleus and cause DNA 
fragmentation characteristic of apoptosis (193). 
Activation of the intrinsic pathway typically stems from toxic stressors such as DNA 
damage or pH alterations (181,191,194-196). Initiation of the intrinsic pathway via these means 
activates a group of pro-apoptotic proteins that are members of the B cell lymphoma-2 (Bcl-2) 
family and known as BH-3-only proteins. BH-3-only protein activation leads to increased 
activity of BAK and BAX either directly (197-200) or through antagonizing anti-apoptotic 
proteins including Bcl-2 and Bcl-2-like protein 1 (194,197,198,201). 
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Figure 12. Molecular Signaling cascades governing the intrinsic and extrinsic pathways of apoptosis in 
mammalian cells. As described in the text, extrinsic pathway initiation occurs classically via FasL, TNFa, or 
PAMP/DAMP binding to their respective receptors activating downstream caspases. Intrinsic pathway activation 
can occur in response to toxic stress or DNA damage giving rise to BH3-only protein activation, which antagonize 
anti-apoptotic proteins Bcl-2, Bcl-XL or MCL1 or directly activate pro-apoptotic proteins BAK and BAX. 
procaspase 9, APAF1 and cytochrome c, following its release from the mitochondria, form the apoptosome which 
activates the effector caspase 3. Figure reprinted with permission from Springer Science and Business Media. 
Article: (41). Copyright 2011.  
Although enterocyte apoptosis is a key physiologic process in gut homeostasis and 
function of the epithelial barrier via the removal of senescent, malfunctioning or harmful cells 
(184) the rate at which apoptosis occurs is a key factor in determining whether the reparative and 
regenerative mechanisms in place will be sufficient to ensure barrier integrity. Loss of integrity 
and ensuing microbe or microbial product translocation will lead to activation of the intestinal 
immune system initiating a dangerous positive feedback loop of bacterial translocation, 
inflammation, inflammation-induced apoptosis and further barrier disruption. The role of TLR4 
in disrupting both enterocyte proliferation and migration were discussed above. Now we 
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consider the direct role of TLR4 and NF-kB induction of enterocyte apoptosis. As mentioned 
previously, NF-kB is critical for a number of cellular process including pro-survival and pro-
apoptotic signals. Studies of mice deficient in NF-kB responses consistently demonstrated 
increased intestinal apoptosis and severe intestinal inflammation compared with wild-type mice 
(202) and increased intestinal injury in response to ischemia-reperfusion injury (203). Also mice 
lacking NF-kB signaling in IECs of the distal small bowel and colon led to increased 
susceptibility to intestinal injury and inflammation in a dextran sodium sulphate-induced colitis 
model partly due to increased rates of epithelial apoptosis (94). These studies are in contrast to 
the induction of apoptosis via NF-kB activation in the newborn small intestine not seen in the 
TLR4-deficient or adult mouse. This significant increase in enterocyte apoptosis serves as a key 
pathogenic factor in the development of NEC (158). TLR4-mediated injury within the newborn 
small intestine is also in stark contrast to previous work in the adult colon in which TLR4 
signaling results in optimal proliferation and protection of colonic epithelia from exaggerated 
apoptosis (204). Differences in injury model (NEC vs Colitis), location of injury (small vs large 
bowel) and age (newborn vs adult) are likely contributing factors to the observed differences. 
This is supported by the demonstration that TLR4 signaling within the colon and adult small 
bowel did not result in apoptosis (158). One possible explanation accounting for such differences 
between the newborn and adult small bowel as well as the adult colon is TLR4 ontogeny. TLR4 
expression within the developing intestine in utero was found to significantly elevated 
throughout the gut during development, then fall shortly after birth, to rise, then fall once more 
immediately after weaning. TLR4 was found to be responsive at each of these time-points, 
including in utero where TLR4 was hyper-responsive to stimulation by LPS following in utero 
injections (113). With the transition from a sterile to a non-sterile environment, as occurs 
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following birth, the gut is rapidly colonized with what will become commensal flora. It is not 
surprising therefore that with premature birth and associated high levels of TLR4 expression, the 
newborn small bowel is significantly predisposed to exaggerated inflammation and NEC. The 
gut inflammation and injury due to higher baseline TLR4 expression in the premature gut is also 
exacerbated by conditions of prematurity including hypoxia and remote infections, both of which 
lead to increased and sustained TLR4 expression and signaling (41,155). However, in the adult 
colon, where TLR4 expression is relatively low, one would expect minimal signaling to occur 
with TLR4 playing more of a homeostatic role than pathologic (41). 
Contributing aspects of TLR4 signaling leading to induction of enterocyte apoptosis in 
the pathogenesis of NEC involves the generation of pro-inflammatory mediators downstream of 
NF-kB activation. iNOS activity remains one of the key downstream effectors up-regulated in 
this setting (205,206). Among the three isoforms of the nitric oxide synthases, which catalyze the 
formation of NO from Arginine and O2, iNOS plays a key role in host immunity and is expressed 
not under normal conditions but during inflammatory states (207). NO generated by iNOS, 
unlike that generated by other NOS isoforms, is not rapidly scavenged by red blood cells into 
nontoxic nitrates. iNOS generated NO is thus free to interact with ROS such as superoxide 
anions yielding the highly toxic intermediate peroxynitrite (ONOO- ) which is significantly more 
reactive than either NO and superoxide (208). Peroxynitrite generation is considered a hallmark 
for the inflammatory response and host defense given its highly effective ability to kill microbial 
targets via its ability to directly oxidize target protein motifs including thiols, iron/sulfur centers 
and zinc fingers significantly disrupting target protein function (209). Peroxynitrite, while not a 
free radical itself, can also lead to damage through its breakdown into highly reactive free 
radicals hydroxide and nitrogen dioxide (210). Peroxynitrite generation can also lead to the 
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nitration of tyrosine residues of proteins. As nitration can serve as an alternative to tyrosine 
phosphorylation, this greatly affects the target protein function leading to disruption of 
intracellular signaling processes (211). As discussed above, exaggerated TLR4 signaling and 
expression are key factors to the pathogenesis of NEC. With TLR4 stimulation by LPS in IECs, 
iNOS expression is significantly up-regulated (170,212) from its low expression at baseline in 
distal ileal tissue (213). Increased and sustained iNOS activity can lead to intestinal barrier 
failure not only through direct inhibition of IEC migration, proliferation and induction of 
bacterial internalization but through the induction of enterocyte apoptosis (210). The increased 
enterocyte apoptosis as seen in NEC is strongly correlated to increased peroxynitrite activity 
where apoptotic cells also co-localize with increased 3-nitrotyrosine and iNOS staining 
(206,214). Upon exposure of enterocytes to peroxynitrite, apoptosis occurs via caspase-
dependent pathways discussed above (215) as well as necrosis via inhibition of mitochondrial 
respiration (210). Following TLR4-mediated NF-kB activation in IECs there is a significant 
increase in pro-inflammatory mediators such as TNFα, IL-1, IL-6, platelet activating factor (216) 
which have all been demonstrated to play a role in murine and human NEC pathogenesis 
(210,214,217-219). 
Figure 13 summarizes the key pathogenic features of TLR4 signaling that serve as 
critical factors in the etiology of NEC. The importance to understand the molecular mechanisms 
leading to TLR4-mediated apoptosis in the setting of NEC stems from the fact that it is a 
programmable, reversible, early event in NEC and as such a key therapeutic target for novel 
treatments.  
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Figure 13.Detrimental effects of exaggerated TLR4 activation. Increased TLR4 signaling in conditions conducive 
to increased TLR4 expression (prematurity, hypoxia, inflammation), plays a key role in mediating gut inflammation 
and injury via inhibition of intestinal repair mechanisms: Restitution and Proliferation. IECs lost to apoptosis in the 
epithelium generate gaps within the monolayer potentially compromising barrier integrity. Typically, these gaps are 
quickly filled by migration and proliferation of surrounding IECs. TLR4 activation, however, not only leads to 
exaggerated IEC apoptosis that quickly outpaces the regenerative capacity, but also directly inhibits migration and 
proliferation of surrounding IECs. Therefore, bacteria are more likely to translocate the discontinuous barrier 
leading to immune activation and subsequent sepsis and systemic inflammation. Figure reprinted with permission 
from Springer Science and Business Media. Article: (41). Copyright 2011. 
1.3.5 Modulation	  of	  Enterocyte	  TLR4	  Signaling	  
TLR4 signaling in the intestinal epithelium in response to commensal enteric flora can 
lead to NEC, but this is kept in check by the PRR inhibitory mechanisms discussed previously. 
As an additional example of this method by which TLR4 signaling can be reduced in 
enterocytes, Lotz et al. (80) have shown that the enterocytes of vaginally born—but not C-
section delivered mice—are relatively resistant to TLR4 activation in vitro because of a 
posttranscriptional down-regulation of IRAK-1. Wang et al. (220) have shown that expression of 
MAPK phosphatase 1 leads to a reduction in the extent of signaling through TLR4— and other 
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TLRs—in enterocytes, as a negative feedback loop requiring NF-kB. This phosphatase leads to 
the dephosphorylation of MAP kinases, which are important effectors of TLR4 signaling. Recent 
evidence also suggests that cross-talk between two other innate immune receptors—namely 
TLR9 and NOD2—can prevent exaggerated TLR4 signaling. TLR9 is the receptor in enterocytes 
for bacterial DNA, which is rich in CpG groups and significantly hypomethylated, in contrast to 
mammalian DNA. The Hackam laboratory demonstrated that activation of TLR9 with CpG-
DNA in enterocytes both in vitro and in the newborn intestine led to reduced TLR4 signaling as 
manifest by reduced cytokine production and decreased apoptosis through a mechanism that 
involved the up-regulation of the cytoplasmic inhibitor IRAK-M (113). The reciprocal 
expression of TLR9 and TLR4 was found to influence the extent of TLR4 signaling, and the 
development of NEC was accompanied by a relative increase in TLR4 with a concomitant 
reduction in the protective TLR9 (113). Indeed, these findings may explain the relative 
protective value observed from probiotic administration to infants with NEC (221), as these 
probiotic preparations are rich in bacterial DNA, through which activation of TLR9 on the host 
would be expected to limit TLR4 signaling and reduce NEC severity. In recent experiments, the 
Hackam laboratory has also shown that the cytoplasmic bacterial sensor NOD2—which 
recognizes the bacterial motif MDP and which has risen to recent prominence because mutations 
in NOD2 are linked to the development of inflammatory bowel disease in humans (222)— limits 
TLR4 signaling through posttranslational effects on TLR4 and through the up-regulation of the 
pro-apoptotic protein SMAC (158). From a therapeutic point of view, activation of TLR9 by the 
administration of CpG-DNA or activation of NOD2 with administration of MDP resulted in a 
marked reduction in TLR4-signaling (figure 14) and in the severity of experimental NEC in 
mice. 
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Figure 14.Crosstalk between PRRs as regulators of TLR4 signaling in IECs. The Hackam lab has previously 
demonstrated that NOD2 (158) andTLR9 (113) activation can limit TLR4-mediated apoptosis in IECs and NEC via 
inhibition of Smac and activation of IRAK-M respectively. The putative sequence of events for this regulation 
includes the TLR4-mediated internalization of luminal bacteria, activation of the intracellular PRRs via the PAMPs 
MDP (NOD2) and CpG (TLR9). Figure reprinted with permission from Springer Science and Business Media. 
Article: (41). Copyright 2011. 
These findings not only highlight the mechanisms that maintain levels of TLR4 signaling 
under physiological conditions but also suggest novel therapeutic approaches to this devastating 
disease. These studies raise the possibility that the stimulation of these and other, yet to be 
defined, TLR4 regulatory pathways may provide therapeutic benefit to infants with NEC, or 
alternatively, may serve as a preventive strategy when administered to premature infants who are 
at risk. In order to uncover additional TLR4 regulatory pathways important to the pathogenesis 
of NEC, microarray analysis was performed comparing murine distal ileal tissue of wild-type 
animals subjected to a NEC model to those who were not. A selected table of the microarray 
results is presented in Table 4. Among a host of proteins down-regulated in the setting of NEC, 
the molecular chaperone molecule, Heat Shock Protein 70 (HSP70) was most significant.  
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Gene Name Fold Down- Regulation 
Hspa1a (HSP70) -4.79 
Ly96 -3.70 





Ptgs2 (Cox-2) -2.02 
Table 4.   This table lists the most significantly down-regulated genes that were found in intestinal tissue taken 
from mice subjected to a NEC model compared with healthy controls 
1.4 MOLECULAR	  CHAPERONES	  
Along with the discovery that the linear polypeptide chain contained all necessary information 
for a specific protein’s primary, secondary and tertiary structure (223), protein folding was 
believed to occur spontaneously. However this notion is very unlikely due to the Levinthal 
paradox which refutes that peptide chains undergo an exploration of possible conformations as 
this would require a physiologically unrealistic time to “find” the correct conformation (224). 
Repulsive and attractive forces contained in the chain restrict the possibilities and direct folding 
through the generation of various folding intermediates (225,226). While some proteins do not 
require assistance in assuming their final proper (i.e. functional) structure, for a significant 
number of others, assistance is fundamental to not only generate native proteins but prevent 
detrimental partially or misfolded aggregate formation. Aggregate formation can occur among 
these non-native protein intermediates due to exposed hydrophobic residues contained within the 
polypeptide chain and are highly toxic in eurkaryotes (224,227). Given the propensity of newly 
translated peptide chains to undergo aggregate formation most chaperones interact with these 
chains co-translationally alongside the ribosome (224). Subsequently a molecular chaperone is 
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broadly defined as any protein that interacts, stabilizes, or aids a non-native protein or peptide 
chain acquire its native structure but not present within that final native structure (228,229). 
Chaperones are involved in a vast number of cellular processes including nascent peptide chain 
folding, refolding of misfolded or denatured proteins and proteolytic degradation of proteins 
alongside Ubiquitin and the proteasome. Chaperones, like the Heat Shock Proteins recognize and 
bind non-native hydrophobic residues and promote, via ATP-dependent binding and release steps 
(224).  
1.5 HEAT	  SHOCK	  PROTEINS	  
Heat Shock Proteins (HSPs) encompass a family of highly conserved across virtually all 
living organisms cytoprotective molecular chaperones integral to proteostasis and protection 
against a variety of cellular stresses (230). HSPs, so named from their initial description, by 
Ritossa in the 1960s, as being strongly up-regulated upon heat exposure (231) are more 
accurately thought of as stress response proteins. They are potently induced by a variety of 
stresses, both physiologic and pathologic. These stresses lead to protein misfolding, aggregation 
or disruption of regulatory protein complexes and HSP induction in an attempt to restore cellular 
balance(232). Additionally, HSPs are both conditionally expressed or inducible and behave as 
molecular chaperone molecules for other cellular proteins. Their chaperone function, as 
discussed above, is critically important to the proper folding and refolding of unfolded or 
misfolded nascent peptide chains, respectively. As also important for proper proteostasis, HSPs, 
along with ubiquitin and the proteasome, are central to the degradation of damaged or incorrectly 
folded proteins, again as a result of both physiologic or pathologic processes (233,234). 
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Mammalian HSPs have been stratified into two different groups: High and low molecular weight 
(Table 5). 
Table 5.List of major HSP families and family members. The table depicts the subcellular localization of each of 
the major HSP family members and their respective expression level both at baseline and during settings of stress. 
Table reprinted with permission from Wolters Kluwer Health. Article: (230). Copyright 1999. 
The small HSP family is a group of ATP-independent chaperone HSPs varying between 
~15-30KDa (235). Small HSPs include the prominent member HSP27 which is important to 
protect against protein aggregation (236). HSP27 is able to form significant oligomers in its 
dephosphorylated state (237), but during stress HSP27 phosphorylation is catalyzed by MAPKs. 
Phosphorylation following MAPK activation occurs by a variety of signals including mitogens, 
cytokines such as IL-1b and TNFa as well as ROS (232). HSP27 induction occurs relatively late 
in response to ROS stress, serum starvation or radiation and in a variety of cells and tissue types 
(232). 
Four major members of the high molecular weight subfamily include HSP90, HSP70, 
HSP60 and HSP40. These subfamilies and their individual members can be localized to various 
subcellular compartments and vary in their expression i.e. constitutive versus inducible. Each of 
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the members of this group, aside from HSP40, are ATP-dependent chaperone molecules 
requiring co-chaperone proteins to modulate both their conformation as well as ATP-binding 
(232). Mammalian HSP60 is primarily localized to the mitochondrial matrix but homologues 
have also been detected in extra-mitochondrial sites including the cytosol (238,239). HSP60 
family members are typically constitutively expressed but do demonstrate a moderate induction 
upon stressors, most potently in response to heat (240). Given its localization, HSP60 primarily 
plays a role in the folding as well as degradation of misfolded or denatured mitochondrial 
proteins in an ATP-dependent manner. The ATPase activity of HSP60 is regulated by the small 
co-chaperone HSP10 which, via direct binding of HSP60, subsequently regulates its substrate 
binding (232). A loss of HSP10 significantly affects newly imported mitochondrial proteins 
(241). Prominent members of the HSP90 family include HSP90a and HSP90b (242). HSP90 
family members are quite essential for the viability of eukaryotic cells and as such are very 
highly expressed, constituting nearly 1-2% of all cytosolic proteins with additional capacity for 
induction upon exposure to cellular stresses (232). HSP90 maintains a role in ensuring the 
stability of a number of target proteins through direct and indirect associations. These client 
proteins include ligand-dependent and independent receptors (243,244), including a variety of 
tyrosine and serine/threonine kinases (245,246). HSP90 inhibition leads to the targeting of these 
client proteins for proteosomal degradation.  The HSP70 family represents one of the most well-
conserved and well studied chaperones and encoded by a host, roughly 11, of genes in humans 
(232). HSP70 family members vary in terms of subcellular location, with some members located 
within the cytosol like the highly inducible HSP70 or the constitutively expressed, Heat Shock 
Cognate 70 (HSC70) or localized to mitochondria (mtHSP70). A key HSP70 family member 
resides in the Endoplasmic Reticulum (ER) known as BiP. BiP is a fundamental player in the 
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maintenance of ER homeostasis via resident chaperone functions and a key activator of the 
Unfolded Protein Response (UPR) in settings of ER stress (247). Eukaryotic HSP70s possess 
two functional domains: a N-terminal ATPase domain, like HSP90, critical to its chaperone 
function and a peptide/substrate-binding domain where HSP70-substrate interactions occur via a 
cleft composed of several hydrophobic residues. They also possess a C-terminal a-helical domain 
that functions like a lid of the substrate-binding domain opening and closing under the control of 
the ATPase domain. Contained in the C-terminus is also an EEVD motif important for co-
chaperone associations (Figure 15). HSP70 interacts with a wide-variety of co-chaperone 
molecules that are important supporters of its role in proteostasis such as HSP40, HSP-
organizing protein (HOP), HSP-interacting protein (HIP), BAG-1, BAG-3 and the C-terminus of 
HSP70 interacting protein (CHIP)(232). Co-chaperones are able to interact with either the N or 
C-terminal domains of HSP70 and thereby significantly modify its function. These functions 
include in addition to nascent peptide chain folding, the assembly of multiprotein complexes and 
protein trafficking (248). The ability of HSP70 to protect a variety of cell types from a wide 
variety of apoptosis-inducing stresses is well characterized (235). 
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Figure 15.Structure of the key functional domains of the HSP70 family. HSP70 bears a N-terminal ATPase 
domain critical to inducing conformational changes allowing HSP70 to “catch and release” client proteins in its 
chaperoning cycle depicted in Figure 16 and a peptide-binding domain consisting of a hydrophobic cleft. The C-
terminal “lid” domain of HSP70 additionally contains an EEVD motif critical to HSP70 ability to interact with TPR 
containing co-chaperone proteins such as Hop and the E3 ligase CHIP. The N-terminal domain also binds co-
chaperone proteins including nucleotide exchange factors, GrpE and BAG-1. HSP70 also directly interacts with the 
HSP40 chaperone family critical to nascent peptide chain chaperoning, see Figure 16. Figure reprinted with 
permission from Macmillan Publishers Ltd: Nature Structural & molecular biology. Article: (229). Copyright 2009. 
1.5.1 HSP70	  Family-­‐mediated	  Protein	  Folding	  
Chaperones such as HSP70 function by holding nascent and newly synthesized peptide 
chains in a state to allow for proper folding upon their release into the cytosol. This is in contrast 
to the large cylindrical chaperones known as chaperonins (e.g. HSP60 family members) found in 
the eukaryotic cytosol and organelles like mitochondria, that offer physically confined 
compartments for the entire protein or particular domains to fold sequestered away from the 
cytosol (249). The majority of small peptide chains may fold upon release from the ribosome 
without requiring chaperone interaction. A significant amount of nascent chains reach their 
native state via HSP70-HSP40 assistance with a few number of these requiring additional 
assistance from HSP90 for folding including eukaryotic kinases and other signal-transduction 
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proteins (250,251). Although the importance of the barrel shaped chaperonins has been long 
appreciated, defining an essential role for nascent chain-binding chaperones in protein folding 
initially proved difficult due to the significant redundancy among individual components (249). 
A number of the members these chaperones, such as specialized HSP70 proteins such as Ssb1 in 
yeast species and nascent chain-associated complex (NAC), bind directly to the ribosome near 
the peptide chain exit site and are perfectly positioned to associate with newly synthesized chains 
and dissociate upon chain release from the ribosome (228,252). Longer polypeptide chains 
interact with a second class of nascent chain-binding chaperones, including classical HSP70s, 
which do no directly associate with ribosomes (253-255). These chaperones not only serve to 
stabilize peptide chains but aid in the co- or posttranslational folding or mediate transfer to 
downstream chaperones (253,254,256). 
The classic i.e. non-ribosome binding HSP70 family members localized to various 
subcellular compartments require members of the HSP40 family in aiding with protein folding in 
an ATP-dependent manner (249). As previously mentioned and depicted in Figure 15 above, 
HSP70 is portioned into a N-terminal ATPase domain and a C-terminal peptide binding domain 
which is further divided into a beta-sandwich subdomain with a peptide-binding cleft and an a-
helical latch-like segment that functions similar to a lid for the substrate binding domain (257). 
Target peptides are roughly seven, typically hydrophobic, residues with a preference for leucine 
and isoleucine (228,258). Peptides are HSP70 bound, not only through hydrophobic side-chain 
interactions, but through hydrogen bonds with the peptide backbone itself (257). Rapid binding 
of peptides by HSP70s occurs in the ATP-bound state in which the a-helical “latch” over the 
peptide-binding cleft is in the open position. Maintaining a stable hold upon bound peptides 
requires closure of the latch, which is achieved via a conformational change upon ATP 
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hydrolysis. Cycling between ATP-bound and unbound states is regulated by HSP40 family 
members as well as Nucleotide Exchange Factors (NEF) such as the co-chaperones BAG-1 and 
BAG-2. The C-terminus of HSP40 family members functions as a chaperone in recognizing 
hydrophobic residues and thereby can facilitate recruitment/shuttling of nascent chains to 
HSP70s (259-261).NEFs induce the release of ADP from HSP70 family members and upon 
rebinding ATP the HSP70-Peptide complex dissociates ending the chaperone cycle (Figure 16). 
Figure 16. HSP70-mediated nascent peptide chain chaperone cycle. Nascent peptide chains are bound to HSP40 
following translation by the ribosome. (1) HSP40 shuttles the nascent chains and passes them to the C-terminal 
protein-binding domain ofHSP70 while in direct contact with the chaperone. The peptide-binding domain of HSP70 
is further divided into a beta-sandwich subdomain with a peptide-binding cleft and an a-helical latch-like segment. 
Rapid peptide binding to HSP70 occurs in its ATP-bound state. (2) Subsequent hydrolysis of ATP results in a 
conformational change and “clamping down” of the latch-like a-helical motif ensuring tight binding. (3) NEFs such 
as BAG-1 efficiently exchange ADP for ATP subsequently allowing HSP70 to release previously bound peptides, 
(4) freeing it to bind new chains. (5) released peptides are successfully repaired/folded or shuttled to 
chaperonins/HSP90 via HSP70-Hop for additional chaperoning. Figure reprinted with permission from Macmillan 
Publishers Ltd: Nature Structural & molecular biology. Article: (229). Copyright 2009. 
Other HSP70 homologs such as BIP in the ER cooperate in protein folding with co-
chaperones that lack separate affinity for hydrophobic residues. These HSP70 family members 
may be able to bind longer peptide chains and independent of hydrophobic sequences, which is 
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in contrast to the classical cytosolic HSP70s like HSC70 (262). Although all HSP70s cooperate 
with HSP40 family co-chaperones, most eukaryotic HSP70s may be NEF-independent for their 
general function. The dispensability of these factors stems from the fact that the rate-limiting 
step in the ATPase cycle is the hydrolysis of bound ATP and not the disassociation of the 
resulting ADP (249).The NEF, BAG-1 has been shown to regulate the chaperone activity of 
HSC70 via accelerated release of ADP and competing for ATPase domain binding with HiP 
which stabilizes the ADP bound state. This regulatory activity of BAG-1 has been implicated in 
aiding in the anti-apoptotic function of HSC70 (263). With release of peptides from HSP70s they 
are free to conform to their native state. Slow-folding intermediates can rebind to HSP70s to 
prevent detrimental aggregation. Long peptide chains with multiple domains can be involved in 
folding cycles facilitated by multiple HSP70s aiding the folding of each individual domain by 
preventing/reversing intramolecular misfolding. The discovery of HSP70 isomerase activity 
supports this function as evident by spontaneous refolding of chemically denatured firefly 
luciferase in vitro (264,265). An additional example of chaperone coupling in the eukaryotic 
cytosol is that between HSC70 and HSP90 in the folding of signal transduction proteins (251). 
Substrate transfer between HSC70 and HSP90 is accomplished via the co-chaperone HOP acting 
as a physical linker between the two chaperones. HOP possesses two tetratricopeptide repeat 
(TPR) domains, which bind C-terminal sequences in HSC70 and HSP90 (266). Similar peptide 
transfer mechanisms are in place regulating the transfer of misfolded or non-native peptides from 
these chaperones to the proteasome machinery to facilitate degradation. The co-chaperone CHIP, 
via a C-terminal U-box E3-ligase domain (268,269), associates with the C-terminal domain of 
HSP70 as well as that of HSP90 via its N-terminal TPR domain and targets proteins for 
degradation. Among these proteins is HSP70 itself as a regulatory mechanism of HSP expression 
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(267). CHIP cooperates with BAG-1, which binds to HSC70/HSP70 and to the proteasome 
(270). 
1.5.2 Ubiquitin:	  Modulator	  of	  Degradation	  and	  Signal	  Transduction	  
Ubiquitin (Ub) is a protein that is covalently bound to lysine residues that can either 
trigger proteosomal degradation or protein trafficking of tagged proteins, signal transduction or 
DNA damage responses (114). The process of ubiquitination involves a three-step enzymatic 
reaction catalyzed by three classes of proteins: E1 ubiquitin-activating enzymes, E2 ubiquitin-
conjugating enzymes and E3 ubiquitin ligases (271). E1 enzymes, using ATP, activate ubiquitin 
forming a thioester bond between the catalytic cysteine of the E1 and the C terminal glycine 
residue of ubiquitin. The activated ubiquitin is subsequently transferred to a specific E2 
ubiquitin-conjugating enzyme via another thioester bond. Finally, the E3 ubiquitin ligase 
catalyzes the conjugation of the activated ubiquitin to a lysine residue on specific target proteins 
(114). In humans, over 600 E3 ligases have been identified and classified into different 
subgroups in regards to mechanism of ubiquitin transfer, e.g. direct transfer (HECT E3 ligases) 
and in coordination with E2s via E3 scaffolding (RING E3 ligases) (272). E3 ligases directly 
contact all protein substrates and therefore are believed to confer specificity for targeted 
ubiquitination (114). With the linkage of several Ub molecules upon a specific protein, the target 
protein is shuttled to and bound by the proteasome via these Ub tags to facilitate degradation. 
The proteasomal degradation process yields peptides 7-8 residues long that can be broken-down 
further and recycled into new proteins. Proteosomes are cylindrical complexes containing a core 
of four stacked rings around a central pore. Within the inner surfaces of the two inner rings exist 
three to seven protease active sites bearing chymotrypsin-like, trypsin-like and peptidylglutamyl-
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peptide hydrolyzing activity (273,274). The outer rings function more as gates regulating ATP-
dependent entry of tagged proteins via the recognition of poly-Ub tags by the inner subunits of 
the outer rings (273). The most common proteasome is the 26S containing a 20S core structure 
and two 19S caps. With the critical role of the proteasome in proteostasis, it is not surprising that 
it plays a central role in a number of cellular processes such as cell cycle control (275), apoptosis 
(276-278), viral clearance (279) and antigen presentation (280,281). Following degradation, Ub 
molecules are simultaneously removed and recycled by deubiquitinating enzymes (Figure 17). 
Figure 17.Fundamental steps of client protein ubiquitination and proteosomal degradation. Ubiquitin molecules are 
initially activated via an ATP-dependent coupling to E1 ubiquitin-activating enzymes via thioester linkages. 
Activated ubiquitin species are subsequently transferred to specific E2 ubiquitin conjugating enzymes via another 
thioester bond. E2 enzymes subsequently directly interact with specific E3 ubiquitin-ligase enzymes leading to the 
conjugation of activated ubiquitin molecules to target proteins. The mechanism of ligation differs among two main 
families of E3 ligases, the RING and HECT families. (1) RING E3 ligases facilitate the transfer of ubiquitin 
molecules onto target proteins from the E2 enzyme. (2) HECT E3 ligases facilitate the direct transfer ubiquitin 
molecules onto target proteins from the E3 ligases directly. All E3 ligases make direct contact with target substrates 
and are viewed as conferring specificity for target protein identification. Once poly-ubiquitinated client protiens are 
shuttled and bound to the 26S proteasome, via ubiquitin receptors on the proteosomal 19S caps, for degradation by 
core proteases possessing trypsin-like, chymotrypsin-like and post-glutamylpeptide hydrolyzing activity. Ubiquitin 
tags may be removed prior or during degradation for recycling. Figure reprinted with permission from Macmillan 
Publishers Ltd: Nature Reviews Molecular Cell Biology. Article: (282). Copyright 2008. 
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Polyubiquitination requires the linkage of several Ub molecules via connection of several 
internal lysine residues to form an oligameric Ub chain. Seven lysine residues exist as potential 
linkage sites including the predominant and most well-characterized targets K48 and K63 (283). 
Staggered K48 links typically trigger proteosomal binding and degradation of tagged proteins 
(e.g. IkBα ubiquitination) while K63 links serve as nonproteolytic tags for such processes as 
signal transduction (e.g. TRAF6 ubiquitination), receptor trafficking, kinase activation and the 
DNA damage response (271,283). In addition to K48 and K63, linear linkages can be formed 
between carboxy and amino termini of two Ub molecules (284). Linear polyubiquitination has 
recently arisen as an important player in NF-kB activation, where the regulatory subunit of IKK 
complex, IKKγ, is targeted. The role of linear ubiquitination while important for NF-kB 
activation is still relatively poorly understood (285). Further evidence supports a key role of 
linear poly-Ub of IKKγ in regulating inflammatory and apoptotic NF-kB responses, where 
animals lacking key components of the linear ubiquitin chain assembly complex leads to multi-
organ inflammation and exaggerated NF-kB pro-apoptotic signaling pathways (286,287). 
1.6 THE	  HEAT	  SHOCK	  RESPONSE	  
The Heat Shock Response (HSR) is the term given to the ancient and highly conserved 
response to stresses, both physiologic or pathologic, that may disrupt proteostasis that functions, 
alongside the Unfolded Protein Response (UPR), to return the cell back to homeostasis. The 
HSR and UPR serve as key stress sensors within the cell, regulating expression of members of 
the “proteostasis network” including molecular chaperones, ubiquitin-proteosome machinery as 
well as autophagic activities to clear or repair damaged proteins (233). Figure 18 gives a non-
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exhaustive list of a variety of the stresses that can lead to HSR and UPR activation, including 
heat shock, ROS, noxious chemicals, growth and developmental cues such as growth factors, 
viral/cellular oncogene activation, tissue injury, inflammation and a number of protein 
conformational disorders.  
Figure 18.Initiators of the Heat Shock Response: Pathologic and Physiologic. The HSF1-mediated expression of 
heat shock elements (HSEs) during the HSR occurs following a variety of signals and factors to maintain 
proteostasis. The major inducers of the HSR are classified into four groups including Environmental stress, 
Pathophysiology, Growth/development and Protein conformational diseases. Associated with each major 
subdivision are a non-exhaustive list of representative HSR-inducing conditions within that class. Figure taken from 
(234) 
These stress responses, especially the UPR, also function to ease protein folding burdens 
and loads within the ER in the settings of cell stresses via activation of pathways leading but not 
limited to the regulation of translation, ER-protein folding machinery expression and ER-
associated degradation (234,288,289). The HSR (and UPR) thus maintains diverse cytoprotective  
capabilities and demonstrates the ability to protect not only against subsequent repeat exposure 
to the initial HSR-inducing stressor but to confer tolerance to other stresses (e.g. sub-lethal Heat 
Shock protecting against lethal heat shock or ROS exposure) (234,289). The cell’s ability to 
57 
activate chaperone machinery to respond to significant stresses that cannot be predicted raises 
questions regarding its initial activation. One view holds that chaperones possess a significant 
and excess folding capacity and a fraction of the total chaperone molecules exist in a reserve 
capacity should emergencies arise. The counter and more accurate view to this holds that cells 
maintain little excess chaperone capacity and that their expression is titrated fairly closely, if not 
precisely, allowing the HSR to regulate the proteostasis network with great precision.  
The induction of the HSR depends heavily upon a family of transcription factors known 
as Heat Shock Factors (HSF), first identified in Drosophila (290,291), and their transcription of 
Heat Shock Elements (HSE) and induce HSP gene expression. The mammalian HSF family 
consists of four members: HSF1-HSF4. Each HSF possess unique and overlapping functions and 
can exhibit tissue-specific expression patterns and interacting protein partners that extend beyond 
solely heat shock response genes (289). HSF1 was originally recognized as the primary stress-
response regulator but recent evidence also supports its role in several developmental processes 
alongside HSF2 and HSF4, whereas HSF4 is the only HSF to date with no ascribed role in the 
HSR (289). Work utilizing Hsf1 knockout murine and cell models have demonstrated that HSF1 
is a requirement for transactivation of HSP genes and thus maintaining cellular tolerances to 
stress including thermotolerance (292-295). HSF1 is constitutively expressed in most tissues and 
cell types but in an inactive state during a lack of stress stimuli (296). HSF1 DNA-binding and 
activation capacity are regulated via multiple post-translational mechanisms, protein-protein 
interactions and subcellular localization. Mammalian HSF1 has intrinsic stress-sensing capability 
as it can be homotrimerized from its monomeric form in response to thermal or ROS stress (297-
299). HSF1 activation relies on formation of DNA-binding trimerization as the initial step in 
HSF1 activation in all eukaryotes (300). Extensive evidence exists demonstrating HSF1 interacts 
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with a number of HSPs at different phases of the activation cycle. Monomeric HSF1 exists in a 
weak complex with HSP90 and HSP70, preventing HSF1 trimerization in the absence of stress. 
Following stress stimuli, HSP90 and HSP70 disassociate from HSF1 in order to perform 
chaperone functions directed at proteins damaged or misfolded due to the inciting stress, thereby 
freeing HSF1 for trimerization(301-303)(Figure 19). HSF1 trimer formation is mediated by 
arrays of hydrophobic heptad repeats (HR-A and HR-B) that form a coiled-coil (304,305). An 
additional hydrophobic array HR-C functions to curb spontaneous trimer formation (306-308). 
Trimers can also be kept inactive when its regulatory domain remains bound to a multi-
chaperone complex including HSP90 and the co-chaperone p23 (302,309-312). Activated HSF1 
trimers can interact with HSP70 as well as HSP40 but does not suppress DNA-binding activity 
or post-translationally modify HSF1 but inhibits transactivation capacity via direct interaction 
with the transactivation domain of HSF1 repressing HSE transcription (303). Thus providing a 
key negative feedback mechanism to regulate HSP expression during stress and post-stress 
resolution. The degree of HSR activation is assumed correlative to levels of chaperones and 
nascent/misfolded peptides (289). 
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Figure 19.Activation and attenuation of HSF1-mediated HSE transcription. (1) Inactive HSF1 monomers exist in 
complex with HSP70 and HSP90 preventing its trimerization and phosphorylation. (2) With stress, proteostasis is 
disturbed yielding a rise in misfolded/damaged proteins. (3) HSP70 and HSP90 disassociate from HSF1 to perform 
critical cytoprotective HSR functions. (4) HSF1 is free from inhibition and (5) rapidly trimerizes and translocates to 
the nucleus (6) where it is subsequently phosphorylated and bound to HSEs. (7) Activated HSF1 transcribes heat 
shock genes leading to (8) heat shock mRNA translation. Newly synthesized chaperones continue to aid in HSR 
responses to the inciting stress. (9) Following stress resolution induced chaperones function to again form 
inactivating complexes with HSF1 as well as the targeted degradation of the induced chaperones themselves, 
returning chaperone expression to baseline. Figure taken from (224) 
HSF1 is subjected to extensive post-translational modification including acetylation, 
phosphorylation and sumoylation. HSF1 contains several stress-inducible phosphorylation sites 
contributing to its transactivation activity (313,314). Additionally, phosphorylation of other sites 
of HSF1 can lead to conjugation of small ubiquitin-related modifier (SUMO) to lysine residues 
(315). Phosphorylation-dependent sumolaytion of HSF1 inversely correlates to the severity of 
heat stress, where SUMO conjugation is absent when maximal HSF1 is required (316). Also, 
given that transactivation capacity is significantly decreased upon sumolaytion, this serves as an 
additional regulatory mechanism of the HSR (289). Acetylation of HSF1 occurs on a much 
greater time scale and coincides more with the attenuation phase of the HSF1 activation cycle, 
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leading to transcriptional repression affecting DNA binding to HSEs. This can be reversed by 
SIRT1 activity thereby maintaining HSF1 in a competent state for DNA-binding. Together with 
HSP expression level, SIRT1 plays an important role in HSF1 activity (289). 
Given the critical role of HSPs in a number of cellular processes, pharmacologic 
modulators of HSFs has garnered some interest in several fields.  Hyperactivation of HSFs and 
increased HSP expression have been implicated in tumorigenesis leading to HSF1 inhibitors as 
potential therapeutics (317). Several HSF1 inducers have been proposed including the HSP90 
inhibitors 17-AAG (318) and Geldanamycin (319) as well as Celastrol (320). As an example, 
Celastrol, which possesses anti-oxidant activity and is a natural compound isolated from the 
Celastreace family of plants, activates HSF1 and induces HSP expression profiles with nearly 
identical kinetics to that of heat shock. Inducers of the HSR and subsequent up-regulation of 
HSPs may serve as a possible therapeutic for several disorders (320,321). 
1.7 HEAT	  SHOCK	  PROTEINS	  AS	  MODULATORS	  OF	  APOPTOSIS	  
Induction of the HSR leads to HSP induction, which have been shown to intersect and 
inhibit apoptosis via interfering with caspase activation. Overexpression of HSP27, HSP60, 
HSP70 and HSP90 inhibit apoptosis via blocking caspase activation in a variety of cell stresses 
such as accumulation of misfolded proteins, ROS or DNA damage (322-325). Strategies aimed 
at knocking down expression of these HSPs subsequently renders the host cell significantly more 
sensitive to various apoptotic stimuli (326-329). Selective depletion of HSP70 is sufficient to 
lead to apoptosis in certain cells even in the absence of stimuli such as seen in malignancies 
(330,331). HSPs play a role in inhibiting apoptosis initiated from either the intrinsic or extrinsic 
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pathways with multiple interceding points along each individual pathway (232) (Figures 20 and 
21). 
1.7.1 TARGET:	  Upstream	  Signaling	  
Upon growth factor binding a number of survival signaling pathways can be activated. 
One such pathway includes the phosphatidylinositol 3-kinase (PI3-K) pathway. PI3-K functions 
to phosphorylate inositol lipids in the plasma membrane leading to recruitment and activation of 
AKT. AKT itself can target a number of apoptotic proteins (332,333), including Bad (334) and 
caspase 9 (335). HSP27, as well as HSP70, have been demonstrated to promote anti-apoptotic 
signaling via interactions with the kinase AKT, an association that has proved critical to AKT 
activation in stressed cells (336,337). HSP27 also plays a role in cytoskeleton stabilization 
during bouts of cellular stress, which includes effects upon mitochondria membrane stabilization, 
preventing the critical apoptotic event of cytochrome c release (338). HSP27 has also been 
implicated in preventing TNFα-induced apoptotic signals, in cancer cells, via the increased 
ubiquitination of IkBα and subsequent NF-kB transcription of anti-apoptotic genes including 
Bcl-2, Bcl-xL and IAPs (232,339). Targeted degradation of the cell cycle protein p27kip1 by 
HSP27 under conditions of stress leads to an increase in cell proliferation following stress 
resolution (340). 
HSP70 has also been shown to inhibit stress-induced kinases like Apoptosis Signaling-
regulating Kinase (ASK1). HSP70 down-regulation increases ROS-mediated ASK1 activation 
and apoptosis (341). HSP70 binds to and inhibits c-Jun N-terminal Kinase (JNK) for which its 
ATPase domain is dispensable (324,342,343) and loss of HSP70 expression leads to exaggerated 
apoptosis via exaggerated JNK activation in response to hyperosmolarity (344). HSP70 
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additionally was demonstrated to also affect p38 kinase activity (345). HSP70 has also been 
shown to interact with transcription factors involved in expression of Bcl-2 proteins. Bcl-2 and 
Bax are gene targets of p53, where p53 represses and induces transcription of Bcl-2 and Bax 
respectively. HSP70/HSC70 may play a role in masking nuclear localization sequences of p53, 
thereby impeding its nuclear import preventing apoptosis in response to DNA damage, a 
pathway at play in many tumor cells (346,347). The role of HSP70 regulating NF-kB remains 
fairly controversial. Evidence supports a role of cytoplasmic HSP70 inhibiting NF-kB activation 
while membrane bound HSP70 leading to its activation (348,349). Elevation of HSP70 to 
significant levels can actually lead to increased sensitivity to TNFα-induced apoptosis via 
inhibition of NF-kB survival pathways. This effect however could be the result of HSP70 
promoting elimination of cells with significant DNA damage where tumor suppressor genes 
induce expression of HSP70s in response to significant DNA-damage potentiating TNFα activity 
(84). HSP70-mediated inhibition of NF-kB activation is perceived to be due to inhibition of both 
IKK activation and ubiquitination of IkBα especially important in the regulation of inflammatory 
signaling cascades (350,351). 
HSP90, like the HSPs mentioned above, regulates activity and stability of various 
transcription factors and kinases including the aforementioned NF-kB, p53 (352), AKT, and JNK 
(353). HSP90 significantly affects NF-kB survival pathway activity via interaction with the IKK 
complex and is in fact an additional component of the IKK complex in addition to Cdc37. 
HSP90 and Cdc37 exist bound to one another as well as IKKα/IKKβ. Inhibition of HSP90 
disrupts this complex leading to impediment of TNF-induced IKK recruitment and NF-kB 
activation (354). HSP90 mediates survival also through stabilization of phosphorylated AKT 
molecules. Activated AKT promotes the phosphorylation, i.e. inhibition of Bcl-2 family member 
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Bad and caspase 9, and prevents their pro-apoptotic activity (335). Activated AKT also leads to 
activation of NF-kB survival pathway signals (333). 
1.7.2 TARGET:	  Mitochondria	  
Touched upon briefly above, HSP27 plays an important role in the prevention of 
cytoskeletal disruption in response to stress, but also attenuates Bid relocalization to the 
mitochondria preventing cytochrome c release (335) as well as release of Smac (355). Similarly, 
HSP70 prevents the translocation of Bax and subsequent outer membrane permeability 
facilitating cytochrome c and Apoptosis-Inducing Factor (AIF) release, which can trigger 
caspase-independent apoptosis via direct translocation to the nucleus (356). HSP60 and Bax 
complex formation is also a likely route of apoptosis prevention where targeted knockdown of 
HSP60 yields an increase in Bax and decreased Bcl-2 culminating in increased apoptosis in 
cardiomyocytes (357,358). More generally HSP60 also plays an important function in ensuring 
proper functioning of the complexes of the ETC safeguarding ATP generation and decreased 
cytochrome c release (359). Interestingly, HSP90 expression within mitochondria in tumor cells, 
not typically seen in normal tissues, regulates mitochondrial permeability and cytochrome c 
release (360). Also evidence exists of HSP90β forming complexes with Bcl-2 leading to 
apoptosis prevention in macrophages and dendritic cells (361). 
1.7.3 TARGET:	  Post-­‐Mitochondria	  
HSP27-mediated apoptosis prevention may also occur post-cytochrome c release via its 
sequestration, preventing capsase activation (362,363) or association with and prevention of 
activation of caspase 3 directly (364). HSP27 can also increase oxidant tolerance via both a 
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reduction in ROS levels (365) and neutralization of oxidized proteins directly (366). The ability 
of HSP27 to stabilize cytoskeleton also confers an ability to regulate membrane bleb formation 
(367,368). HSP70’s and HSP90’s role in apoptosis prevention has also been extended to direct 
interactions with APAF-1 preventing recruitment of caspase 9 into the apoptosome and caspase 3 
activation (369-371). The ATPase domain of HSP70 was subsequently found to be necessary for 
this activity (372). HSP70’s role in prevention of apoptosis extends further downstream of 
caspase 3 inhibition as it has been shown to prevent apoptosis in the face of activated caspase 3 
via inhibition of phospholipase A2 and characteristic nuclear changes (247). Interestingly, CAD, 
downstream of caspase 3 activation, requires HSP70 and HSP40 in addition of ICAD for proper 
folding and enzymatic activity, thereby highlighting it as an additional target for HSP70-
mediated cytoprotection. ICAD-mediated CAD inhibition occurs via recognition and binding of 
a CAD folding intermediate in association with HSP70-HSP40 (373). HSP90 has additionally 
been implicated in modulating affects downstream of caspase activation including intermediate 
filament stabilization, a key target of activated caspases leading to nuclear condensation and 
fragmentation (374). It is important to note that evidence has implicated both HSP60 and HSP10 
as maintaining pro-apoptotic roles following their release from mitochondria via direct 
association with procaspase 3 and enhancing its activation by cytochrome c via the apoptosome 
(375,376).  
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Figure 20. Schematic depicting regulation of the intrinsic apoptosis pathway via HSPs. HSPs can block 
mitochondrial apoptotic signals such as induced via ROS, through interaction upstream from the mitochondria 
through modulation of stress kinase (AKT, JNK, ERK) activity. HSPs can intercede at the mitochondrial level via 
limiting cytochrome c release (HSP27 membrane stabilization, HSP70 and HSP60 inhibition of Bax, HSP90 
interaction with Bcl-2), blocking APAF1-cytochrome c interactions. HSPs also can intercede at the post-
mitochondrial level via direct interaction with APAF1 (HSP70/HSP90), cytochrome c (HSP27), or caspase 3 
(HSP27). These intersection points lead to a decrease in effector caspase activation and/or activity preventing 
initiation of apoptosis by limiting Caspase-activated DNase (CAD) activity among other mechanisms. Figure 
reprinted with permission from John Wiley & sons Inc. Article: (232). Copyright 2008. 
1.7.4 TARGET:	  Extrinsic	  and	  Caspase-­‐Independent	  Pathway	  
With specific respect to the extrinsic apoptotic pathway, HSP27 and HSP70 have been 
demonstrated to inhibit Fas-induced apoptosis (377). HSP27 and HSP70/HSP90 may inhibit 
TNFα-induced cell death via blockade of Bid translocation and Bid cleavage by activated 
caspase 8 (378). In addition to preventing Bax translocation and AIF release, HSP70 can also 
directly bind AIF and prevent its translocation to the nucleus (379-381). Stress stimuli have been 
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demonstrated to lead to translocation of lysosomal proteases from the lysosome to the cytosol 
serving as an important death pathway (382). These inciting stresses include TNFα (383,384), 
Fas (385), p53 activation (386), ROS (385,387) and growth factor withdrawal (385). Cathepsins 
are the best characterized of the released lysosomal proteases and demonstrated to lead to 
increased mitochondrial outer membrane permeability (383,386,388-390). HSP70 has been 
demonstrated to be expressed within endolysosomal membranes where it can inhibit release of 
cathepsins into the cytosol (391,392). 
Figure 21.Schematic depicting regulation of the extrinsic and caspase-independent apoptosis and apoptosis-like 
pathways via HSPs. Both HSP70 and HSP90 can interact with RIP1 at the death receptor level blocking signal 
transduction and promoting survival. HSP70 and HSP90 can also block caspase 8 activation via recruitment of 
TRAIL/FADD and FLIP respectively.HSP70 can directly inhibit AIF activity and prevent release of lysosomal 
proteases (such as cathepsins) into the cytosol. HSP70 and HSP90 can also limit Bid cleavage while HSP27 can 
affect Bid translocation to the mitochondria prevent mitochondrial membrane disruption. HSP70 can also limit stress 
kinase ASK1 activity limiting death receptor signaling. Figure reprinted with permission from John Wiley & sons 
Inc. Article: (232). Copyright 2008. 
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1.8 CURRENT	  STUDY	  RATIONALE	  
As previously mentioned, a significant focus of NEC research is aimed at the specific 
targeting and modulation of TLR4 signaling. Such therapies have been demonstrated to possess 
great potential in limiting the severity of NEC. Our lab specifically has identified a number of 
key regulators of TLR4 signaling that have not only furthered our understanding of NEC 
pathology but represent promising avenues for pursuing and developing directed NEC therapies. 
Among these are TLR9 (113), NOD2 (158) and most recently EGFR (117). As shown in table 4, 
microarray analysis of ileal tissue obtained from wild-type mice subjected to our murine model 
of NEC demonstrated a significant decrease in HSP70 expression when compared with healthy 
controls. Given our previous findings indicating that TLR4 is significantly up-regulated during 
and reciprocally expressed in comparison to TLR9 and NOD2 in murine and human NEC, we 
hypothesized HSP70, like TLR9 and NOD2, also negatively regulates TLR4 in NEC. We next 
sought to test whether HSP70 may represent a previously unrecognized inhibitor of TLR4 
signaling in the enterocyte and, by extension, a key pathogenic factor of NEC. Specifically, the 
aims of the current work are summarized below: 
1.To assess the protective effects of HSP70 induction on TLR4-mediated intestinal injury
and repair. 
Given the role of HSP70 in mediating both apoptosis and inflammation we specifically 
sought to determine whether induction of HSP70 could decrease TLR4-mediated NF-kB 
activation, pro-inflammatory cytokine production and apoptosis. We additionally sought to 
determine the mechanism of action by which HSP70 could limit TLR4 signaling. Given HSP70’s 
role in proteostasis as a molecular chaperone and reciprocal expression with TLR4 we tested 
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whether HSP70 and TLR4 could form inhibitory complexes leading to ubiquitination and 
degradation curbing exaggerated TLR4 expression 
2. To determine the role of HSP70 in the prevention and treatment of Necrotizing
Enterocolitis via TLR4 inhibition. 
Through the use of genetically modified mice either over-expressing HSP70 specifically 
within the intestinal epithelium or globally HSP70-deficient we tested the role and relevance of 
HSP70-mediated modulation of TLR4 in the setting of NEC. In order to test whether HSP70’s 
protective role could be manipulated for clinical gain we utilized a known pharmacologic 
inducer of HSP70 to determine whether its introduction could lead to prevention and/or 
treatment of NEC.   
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2.0	   INTRACELLULAR	  HEAT	  SHOCK	  PROTEIN-­‐70	  NEGATIVELY	  
REGULATES	  TOLL-­‐LIKE	  RECEPTOR	  4	  SIGNALING	  IN	  THE	  NEWBORN	  
INTESTINAL	  EPITHELIUM	  
2.1 ABSTRACT	  
Necrotizing enterocolitis (NEC) is the leading cause of gastrointestinal-related mortality in 
premature infants, and it develops under conditions of exaggerated TLR4 signaling in the 
newborn intestinal epithelium. Because NEC does not develop spontaneously, despite the 
presence of seemingly tonic stimulation of intestinal TLR4, we hypothesized that mechanisms 
must exist to constrain TLR4 signaling that become diminished during NEC pathogenesis and 
focused on the intracellular stress response protein and chaperone heat shock protein-70 
(HSP70). We demonstrate that the induction of intracellular HSP70 in enterocytes dramatically 
reduced TLR4 signaling, as assessed by LPS-induced NF-kB translocation, cytokine expression, 
and apoptosis. These findings were confirmed in vivo, using mice that either globally lacked 
HSP70 or overexpressed HSP70 within the intestinal epithelium. TLR4 activation itself 
significantly increased HSP70 expression in enterocytes, which provided a mechanism of auto-
inhibition of TLR4 signaling in enterocytes. In seeking to define the mechanisms involved, 
intracellular HSP70-mediated inhibition of TLR4 signaling required both its cochaperone-
binding EEVD domain and association with the co-chaperone CHIP, resulting in ubiquitination 
and proteasomal degradation of TLR4. The expression of HSP70 in the intestinal epithelium was 
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significantly decreased in murine and human NEC compared with healthy controls, suggesting 
that loss of HSP70 protection from TLR4 could lead to NEC. In support of this, intestinal HSP70 
overexpression in mice and pharmacologic up-regulation of HSP70 reversed TLR4-induced 
cytokines and enterocyte apoptosis, as well as prevented and treated experimental NEC. Thus, a 
novel TLR4 regulatory pathway exists within the newborn gut involving HSP70 that may be 
pharmacologically activated to limit NEC severity.
2.2 INTRODUCTION	  
Necrotizing enterocolitis (NEC) is the leading cause of death from gastrointestinal disease 
in premature infants, and it is characterized by the sudden onset of feeding intolerance that 
rapidly progresses to abdominal distention, systemic sepsis, and death due to acute necrosis of 
the intestine (393). The intestinal epithelium in infants with NEC displays exaggerated 
enterocyte apoptosis and mucosal disruption, which is widely thought to lead to the trans-luminal 
passage of indigenous microbes and an unbridled activation of the host immune system (219). In 
seeking to determine the inciting molecular mechanisms leading to the development of this 
cascade, we (155,159) and other investigators (156,163) determined that activation of the innate 
immune receptor TLR4 within the intestinal epithelium plays an important role in NEC 
pathogenesis. Specifically, TLR4 signaling in enterocytes leads to increased enterocyte apoptosis 
in vitro and in vivo, whereas inhibition of TLR4 signaling in the newborn intestinal epithelium 
prevents NEC development (155,158,159). Although these studies have clearly placed the 
spotlight on the role of TLR4 in the pathogenesis of NEC, the observation that most premature 
infants do not develop NEC, despite seemingly tonic activation of TLR4 within the gut, raises 
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the possibility that TLR4 signaling must somehow be curtailed within the newborn intestinal 
epithelium to limit disease development. Importantly, however, the presence of negative-
regulatory strategies for TLR4 within the newborn intestinal epithelium and the degree to which 
such strategies may participate in the pathogenesis of NEC remain largely unexplored. 
In the current studies, we test the hypothesis that the intracellular chaperone Heat Shock 
Protein-70 (HSP70) could negatively regulate TLR4 signaling within enterocytes and, by 
extension, that a loss of HSP70 could lead to NEC development through unbridled TLR4 
activation. The heat shock proteins, of which HSP70 is a predominant member, represent a 
family of intracellular proteins that is activated by a variety of stressors and that can assist in the 
delivery of target proteins to the ubiquitin–proteasome system for degradation through co-
chaperone molecules, such as CHIP (394). An intracellular role for HSP70 has not been linked to 
the pathogenesis of NEC nor to regulation of TLR4 within enterocytes, although HSP70 was 
shown to play an important role in themodulation of apoptosis after various forms of stress (395-
398). Through its combined roles of both clearing proteins and modulating cell death, the net 
effect of HSP70 induction within cells is to restore the host to a non-stressed environment(399-
401). Although cytoplasmic HSP70 has not been linked to the regulation of TLR4 signaling 
inside the enterocyte, HSP70 was shown to serve a protective role in the intestine, as 
demonstrated by Chang and colleagues (402,403), although upstream regulatory pathways within 
the gut were not identified. Taken together, these findings in the literature now raise the exciting 
possibility that intracellular HSP70 could represent a novel regulator of TLR4 signaling at 
baseline and in the development of NEC. 
In support of this hypothesis, using enterocytes that either lack or are induced to express 
HSP70, as well as by examining mice that either lack HSP70 or that overexpress HSP70 within 
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the intestinal epithelium, we now determine that intracellular HSP70 limits TLR4 signaling in 
enterocytes and, moreover, that HSP70 plays a central role in the pathogenesis of NEC. The 
mechanism by which HSP70 limits TLR4 signaling in the gut involves an increase in CHIP- 
mediated ubiquitination and degradation of TLR4 via the ubiquitin–proteasomal pathway. 
Importantly, pharmacologic up-regulation of HSP70 within the intestinal mucosa led to a 
reduction in TLR4 signaling and a decrease in enterocyte apoptosis, leading to attenuation of 
NEC severity. Taken together, these findings illustrate a novel pathway linking the regulation of 
HSP70 with the negative control of TLR4 signaling within the gut and provide evidence that the 
development of NEC results, in part, from exaggerated TLR4-induced enterocyte apoptosis that 
is due, in part, to reduced HSP70 activity. Moreover, these results suggest that pharmacologic 
up-regulation of HSP70 could provide a novel approach to the prevention and/or treatment of 
NEC through the inhibition of TLR4 signaling in the newborn intestine. 
2.3 MATERIALS	  AND	  METHODS	  
2.3.1 Cell	  culture	  and	  reagents	  
IEC-6 enterocytes were obtained from the American Type Culture Collection (Manassas, 
VA). LPS (Escherichia coli 0111:B4 purified by gel-filtration chromatography, >99% pure) 
was from Sigma-Aldrich. The TLR5 ligand flagellin was obtained from InvivoGen. Abs were as 
follows: p65 subunit of NF-kB (Santa Cruz Biotechnology); TLR4 (IMGENEX, Santa Cruz 
Biotechnology [L14]); cleaved-caspase 3 (Cell Signaling); the inducible isoform of HSP70 
(StressGen SPA-810 and Santa Cruz Biotechnology [inducible, K20]); the constitutive (control) 
isoform of HSP70, i.e., HSC70 (StressGen SPA-815); Ubiquitin (Millipore); V5 (GenScript). 
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Where indicated, cells were pretreated with the proteasome inhibitor MG-132 (10μM; 
Calbiochem) 2h prior to the indicated experimental condition. IEC-6 enterocytes were treated 
with LPS at concentrations that we have shown to be present in mice and humans with NEC (i.e. 
50 μg/ml)(155). 
2.3.2 Preparation	  of	  lentiviruses	  and	  cell	  transfection
Lentiviruses expressing V5-tagged HSP70-dominant–negative C-terminal deletion mutant 
(ΔEEVD), wild-type HSP70, small interfering RNA (siRNA) to HSP70, CHIP HSP70-docking 
N-terminal mutants (K30A), CHIP C-terminal U-Box (H260Q) mutants, and LacZ were 
generated using a combination of ViraPower HiPerform Lentiviral and Lentiviral pLenti6.3/V5-
DEST Gateway expression system (Invitrogen). In brief, the recombinant V5-tagged 
pLenti6.3/V5-DEST expression plasmids expressing wild-type and dominant-negative C-
terminal deletion mutant (ΔEEVD) HSP70, CHIP HSP70-docking mutants (K30A), CHIP U-
Box (H260Q) mutants, and LacZ were first generated using Gateway directional TOPO cloning 
systems (Invitrogen). V5-tagged pLenti6.3/V5-DEST expression plasmids are under the control 
of immediate early promoter human CMV and contain WPRE and cPPT elements, which yields 
cell-specific, high- performance expression of recombinant proteins. Recombinant V5-tagged 
pLenti6.3/V5-DEST expression plasmids were end sequenced to verify the correct directional 
cloning. High-expression lentiviral particles were next generated by co-transfection of 
recombinant V5-tagged pLenti6.3/V5-DEST plasmids and ViraPower Packaging Mix in 
receptive 293FT cells and used for transduction in destination IEC-6 cells for expression of 
recombinant proteins. mRNA and protein expression of recombinant proteins were verified by 
quantitative RT-PCR, Western blot, and immunofluorescence staining. Cells were transduced 
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with virus particles 48h prior to additional treatment. 
IEC-6 cells were pretreated with either HSP70 siRNA (100nM; Dharmacon) via 
Lipofectamine LTX (Invitrogen), according to the manufacturer’s directions, or a negative 
control siRNA that is directed at no known target for 48h in antibiotic-free media at 37 ̊C in a
humidified chamber with 5% CO2. The media were changed, and cells were treated with LPS 
and assessed for apoptosis, NF-kB translocation, and/or cytokine expression. 
The NF-kB promoter GFP-reporter system was generated via the pPACKF1 Lentivector 
Packaging kit (System Biosciences) using the pSIF1-H1-siLuc-copGFP positive-control 
expression plasmid and delivered via lentiviral transduction of IEC-6 cells 48h prior to 
stimulation with LPS and/or heat treatment, as described above. 
2.3.3 HSP70	  induction	  and	  knockdown
For the induction of HSP70, IEC-6 cells were placed in an incubator at 42 ̊C (5% CO2 and
23% O2) for 45min, followed by either a 4h (LPS-mediated apoptosis analysis) or 8h (NF-kB 
translocation assay) recovery period at 37 ̊C under otherwise the same ambient conditions, after
which they were exposed to the indicated treatment. In parallel, IEC-6 cells were treated with 
Celastrol (3μM in DMSO) for 30 min at 37 ̊C and allowed an 8h recovery period at 37 ̊C prior to
treatment with LPS. Targeted knockdown of HSP70 was accomplished via transfection with 
siRNA to HSP70 or siRNA against no known target. Chemical inhibition of HSP70 was 
performed via 2h pretreatment with quercetin (20 μM; Sigma) in DMSO. 
Induction of HSP70 within cells was accomplished in vivo through the administration of 
Celastrol (1 mg/kg), as described below. To confirm that the effects of this compound on TLR4 
signaling occurred through up-regulation of HSP70, all studies were performed in HSP70-
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deficient mice after injection of Celastrol for comparison, as described below 
2.3.4 Experimental	  endotoxemia	  and	  NEC	  
All experiments were approved by the Children’s Hospital of Pittsburgh Animal Care 
Committee and the Institutional Review Board of the University of Pittsburgh. C57BL-6, Swiss 
Webster, HSP70-/-, and mice overexpressing HSP70 on the villin promoter (HSP70villin), as well 
as their appropriate wild-type controls, were generated as described (402,403) or obtained from 
The Jackson Laboratory. All animals were age and sex matched prior to use. Experimental NEC 
was induced in 10d-old mice, as we described (113,158,159), using formula gavage (Similac 
Advanced infant formula [Ross Pediatrics]/Esbilac canine milk replacer, 2:1) five times/d and 
hypoxia (5% O2, 95% N2) for 10 min in a hypoxic chamber (Billups-Rothenberg) twice daily for 
4d. Where indicated, mice were administered Celastrol (1 mg/kg) via i.p. injections 1d prior to 
the model and on day 3 of the model. Volume-matched DMSO was administered as a vehicle 
control in all Celastrol-treatment models. The severity of disease was determined on histologic 
sections of the terminal ileum by a pediatric pathologist, who was blinded to the study condition, 
according to the work of Radulescu et al. (404), as follows: 0: normal intestine; 1: epithelial 
lifting or separation; 2: sloughing of epithelial cells to the mid-villous level; and 3: necrosis of 
the entire villous. This protocol results in the development of patchy necrosis involving the small 
intestine similar to human NEC, with an increase in circulating cytokines that mimics that seen 
in human NEC (113). 
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2.3.5 Preparation	  and	  processing	  of	  human	  tissue	  from	  infants	  with	  and	  without	  
NEC
Intestinal samples were obtained from human neonates undergoing intestinal resection for 
NEC, for unrelated indications (control), or at the time of stoma closure. All human tissue was 
obtained and processed as discarded tissue via waiver of consent with approval from the 
University of Pittsburgh Institutional Review Board and in accordance with the University of 
Pittsburgh anatomical tissue-procurement guidelines. 
2.3.6 Immunohistochemistry,	  immunoprecipitation	  and	  SDS-­‐PAGE	  
The immunoconfocal microscopy of IEC-6 enterocytes, as well as mouse and human 
intestine, was performed as previously described (405). In brief, cells were fixed in 4%PFA for 
20min, exposed to 0.1% Triton-X for 20min for antigen retrieval. Cells were blocked in 5% BSA 
for 1h and probed with specific antibodies for 1h. Cells were washed in 1x PBS and probed with 
fluorescently labeled secondary antibodies for visualization. In parallel, Cryo-Gel (Cancer 
Diagnostics) frozen sections of terminal ileum were sectioned (6 μm), rehydrated with PBS, and 
fixed with 2% paraformaldehyde. Nonspecific binding was blocked with 5% BSA. Stained 
tissues and cells were evaluated using an Olympus FluoView 1000 confocal microscope under 
oil-immersion objectives. Images were assembled using Adobe Photoshop CS2 software (Adobe 
Systems). 
For immunoprecipitation, IEC-6 lysates were collected, and 500μg total protein was pre-
cleared with 20 μl/sample Agarose Protein A/G beads (Santa Cruz Biotechnology) for 30 min at 
4 ̊C. Samples were centrifuged, and supernatants were collected and treated with Abs to HSP70
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(K20) or ubiquitin, as indicated, or an isotype IgG control Ab and then incubated with Agarose 
Protein A/G beads overnight at 4 ̊C. Samples were then centrifuged, supernatants were discarded,
and beads were washed three times in PBS and resuspended in equal volumes of 2xgel-loading 
buffer and boiled at 95 ̊C for 3min. Lysates were then subjected to SDS-PAGE (177) and
immunoblotted with various Abs (1:1000), as indicated. Blots were developed using ECL 
reagent (ECL-Super Signal; Pierce) and developed on radiographic film. 
2.3.7 Quantitative	  real-­‐time	  PCR	  
Quantitative real-time PCR was performed, as previously described, using the Bio-Rad 
CFX96 Real-Time System (155) and the primers listed in Table 6. In brief, total RNA was 
isolated from the ileal mucosal scrapings of mice that had been breast-fed (control) or induced to 
develop experimental NEC, as well human control and NEC tissues using the RNeasy kit 
(Qiagen) and reverse transcribed (1 µg of RNA) using the QuantiTect Reverse Transcription Kit 
(Qiagen). Gene-specific cDNA was amplified and quantified in a real-time thermal cycler system 
(SYBER Green I; iCycler iQ Real-Time PCR Detection System;). PCR amplification was then 
performed in triplicate. In all cases, water was used instead of cDNA to serve as a non-template 
control. The reaction protocol included pre-incubation at 95°C for 15 min to activate AmpliTaq 
Gold DNA Polymerase (Applied Biosystems) and amplification for 40 cycles (15 s at 95°C, 30 s 
at 56°C, and 60 s at 72°C). Where indicated, gene expression was assessed on 2.5% agarose gels
using ethidium bromide staining. Images were obtained with a Kodak Gel Logic 100 Imaging 
System using Kodak Molecular Imaging software. The expression of the following genes by 
quantitative RT-PCR was measured relative to the housekeeping genes b-actin and GAPDH. 
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Table 6. Table of primers used for the detection of specific mRNAs in the current work. Table
reprinted with permission from The American Association of Immunologists, Inc. Article: 
Copyright 2012 
2.3.8 Determination	  of	  enterocyte	  signaling	  and	  mucosal	  injury	  in	  response	  to	  TLR4	  
activation	  
For the determination of NF-kB translocation, IEC-6 cells were treated with LPS (50 
μg/ml, 45 min). The extent of NF-kB translocation was determined as described(113), using an 
adaptation of the methodology of Ding and Li (406). In brief, a threshold limit was set based 
upon the emission signal for the nuclear stain DAPI in serial micrographs of cells that were co-
stained for the p65 subunit of NF-kB, whereas a corresponding cytoplasmic region of interest 
was defined by stenciling a circular region, 12 pixels beyond the nucleus, upon each cell. The 
average integrated pixel intensity pertaining to the corresponding NF-kB emission within the 
cytoplasmic and nuclear regions was then determined for >200 cells/treatment group, in at least 
four experiments per group, using Meta-Morph software version 6.1 (Molecular Devices). 
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The release of IL-6 from IEC-6 cells was determined by an ELISA kit (R&D Systems), 
according to the manufacturer’s instructions. 
Enterocyte apoptosis was determined in IEC-6 cells after 16h of treatment with LPS under 
concentrations that we measured in NEC(155) (50 μg/ml) by immunostaining with Abs to 
cleaved-caspase 3 and performing confocal immunofluorescent analysis. The number of cleaved-
caspase 3-positive cells was identified in a blinded fashion using MetaMorph software 
(Molecular Devices) and expressed as a percentage of cleaved-caspase 3-positivecells/high-
power field, with >100 fields/experiment studied and >100 cells/field. 
Enterocyte apoptosis in vivo was determined by measuring the percentage of enterocytes 
positive for cleaved-caspase 3 by confocal microscopy per high-power field. More than 50 
fields/sample were evaluated, as we described (158). 
2.3.9 Statistical	  analysis	  
All experiments were repeated at least in triplicate, with >100 cells/high-power field. For 
mouse experiments of endotoxemia, >4 mice/group were assessed; for experiments of NEC, >10 
mouse pups/group were included, and litter-matched controls were included in all cases. 
Statistical analysis was performed using SPSS 13.0 software. ANOVA was used for comparisons 
for experiments involving more than two experimental groups. Two-tailed Student t test was 
used for comparison for experiments consisting of two experimental groups. For analysis of the 
severity of NEC, x2 analysis was performed. In all cases, statistical significance was accepted at 
p <0.05 between groups. 
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2.4 RESULTS	  
2.4.1 Heat	  Shock	  Response	  induction	  limits	  TLR4	  signaling	  in	  enterocytes	  
To determine whether the induction of HSP70 could limit TLR4 signaling, we first briefly 
exposed cultured enterocytes (IEC-6 cells) to conditions known to increase the expression of 
HSP70 (42 ̊C, 45 min Fig. 22A) and then treated cells with the TLR4 agonist LPS at
concentrations that we previously measured from the stool of humans and mice with NEC (155). 
The extent of TLR4 signaling was determined by assessing the extent of NF-kB activation, as 
reflected by the degree of translocation of the p65 subunit of NF-kB from the cytoplasm to the 
nucleus as described in Materials and Methods, the degree of induction of the pro-
inflammatory cytokine IL-6, and the degree of enterocyte apoptosis. As shown in Fig. 22, LPS 
treatment caused a marked increase in NF-kB activation (Fig. 22Di, 22Dii) that was significantly 
reduced following heat treatment (Fig. 22C, 22Diii). Heat treatment also prevented the increase 
in IL-6 expression that occurred in LPS-treated IEC-6 cells (Fig. 22B) (primer sequences for 
quantitative RT-PCR are listed in Table 6) as well as a reduction in the extent of LPS-mediated 
apoptosis, both down to levels similar to untreated control cells (Fig. 22Fi–iii). We used the 
expression of cleaved-caspase 3 as an estimate of apoptosis in these studies, because its 
increased expression was shown to be a terminal event in the apoptosis cascade in enterocytes, 
and it provides a reliable and reproducible estimate of enterocyte apoptosis in both human and 
experimental NEC (41,158,407,408). To determine whether a heat-induced increase in HSP70 
was required for the observed attenuation in TLR4 signaling, cells were exposed to heat after 
siRNA-mediated knockdown of HSP70 in IEC-6 cells (Fig. 22E), which abrogated the 
protection in TLR4 signaling previously observed after heat treatment with regard to the 
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induction of IL-6 expression (Fig. 22B), NF-kB translocation (Fig. 22C), and enterocyte 
apoptosis (Fig. 22F). Taken together, these findings indicate that HSP70 can inhibit TLR4 
signaling in enterocytes. We next sought to investigate the mechanisms mediating this effect and 
focused initially on determining whether an association between HSP70 and TLR4 was required 
for the negative effects of HSP70 on TLR4 signaling. 
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Figure 22.HSP70 induction limits TLR4 signaling in enterocytes. (A) Confocal photomicrographs showing the
expression of HSP70 (green), b-actin (red), and DAPI (blue) in IEC-6 enterocytes that were either untreated (i) or 
exposed to 42 ̊C for 45 min (ii). Quantitative RT-PCR showing the expression of IL-6 (B) or quantification of the
extent of NF-kB translocation (C) in IEC-6 cells that were either untreated (white bars) or exposed to heat (black 
bars) and were either untransfected or were transfected with HSP70 siRNA. Quantification in (C) is based upon >50 
cells/field and >50 fields examined in four separate experiments.*p <0.05, versus untreated control, **p <0.01, 
versus heat control, ***p <0.001, versus control cells transfected with HSP70 siRNA. (D) Confocal 
photomicrographs of IEC-6 enterocytes that were untreated (i), treated with LPS (50 μg/ml, 45 min) (ii), or treated 
with LPS after pretreatment with heat (iii). (E) Representative SDS-PAGE showing lysates of IEC-6 that were 
untreated (control), incubated with PBS alone (vehicle), or transfected with either control siRNA against no known 
substrate (nontargeted siRNA) or siRNA to HSP70 (HSP70 siRNA). Blot was stripped then and reprobed with Abs 
to b-actin. (F) Confocal photomicrographs (i–iv) and quantification (v) of IEC-6 enterocytes that were untreated (i), 
treated with LPS in the absence (ii) or presence of pre-exposure to heat as above (iii), or pretreated 48 h prior with 
siRNA to HSP70, as in (iv). Representative images are taken of >50 fields examined with >50 cells/field in four 
separate experiments. Scale bar, 10um. Representative apoptotic cells are indicated by arrows. *p<0.05, versus 
control, **p <0.01, versus LPS control, ***p <0.001, versus heat+HSP70 siRNA saline. Figure reprinted with 
permission from The American Association of Immunologists, Inc. Article: Copyright 2012 
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2.4.2 An	  EEVD-­‐mediated	  association	  between	  TLR4	  and	  HSP70	  is	  required	  for	  the	  
inhibition	  of	  TLR4	  signaling	  in	  enterocytes	  by	  HSP70	  
The effects of HSP70 on target proteins are largely influenced by interactions with 
accessory proteins called co-chaperones (409,410). In a variety of cell types, HSP70 regulates 
the intracellular function and fate of proteins through the formation of direct protein–protein 
interactions that occur largely through an EEVD-binding domain in its C-terminus 
(266,411,412). To investigate whether an association between TLR4 and HSP70 was required 
for the negative effects on TLR4 signaling, IEC-6 cells were stably transduced with lentivirus 
expressing either LacZ as a vector control or with HSP70 bearing a truncation mutation in the 
EEVD domain while sparing the N-terminal ATPase domain, as described (413) (Fig. 23Ai). 
After LPS treatment, cells were subjected to immunoprecipitation using Abs to HSP70 in the 
absence or presence of heat exposure. As shown in Fig. 23Ai, TLR4 was detected in 
immunoprecipitates obtained from IEC-6 lysates that had been transduced with control vector, 
and this association was increased after heat exposure. By contrast, the stable delivery via 
lentiviral transduction of a mutant HSP70 lacking the C-terminus EEVD-binding domain 
markedly reduced the ability to detect TLR4 in the immunoprecipitates after LPS treatment, 
which did not vary after heat exposure, indicating that the EEVD mutation resulted in a reduction 
in the extent of association between HSP70 and TLR4 (Fig. 23Ai). Although heat treatment of 
IEC-6 cells that had been transduced with LacZ vector conferred significant protection from both 
LPS-induced NF-kB translocation (Fig. 23Bi–iii) and enterocyte apoptosis (Fig. 23Ci–iii), this 
heat-mediated reduction in LPS signaling was lost in IEC-6 cells that had been transduced with 
the C-terminus EEVD-binding mutant (Fig. 23Biv–vii, 23Civ–vii). As expected, LPS caused a 
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significantly greater degree of IL-6 expression after transduction of ΔEEVD HSP70 compared 
with nontransfected cells (Fig. 23Bxi), consistent with the reduced effect of HSP70 in inhibiting 
TLR4 signaling in these cells. To further investigate the link between HSP70 expression and 
TLR4 signaling, IEC-6 cells were transduced with lentiviruses expressing wild-type HSP70, 
which resulted in a significant increase in the degree of HSP70 expression compared with 
nontransfected cells (Fig. 23Aii). Importantly, as shown in Fig. 23Bvii–x, compared with LacZ-
transfected control cells, the addition of LPS led to a minimal degree of NF-kB translocation in 
IEC-6 cells that overexpress HSP70, consistent with the notion that these cells are less 
responsive to TLR4 signaling due to the effects of HSP70 on TLR4. Moreover, the degree of 
LPS-induced NF-kB translocation in HSP70–IEC-6 cells was minimally affected by heat 
exposure, consistent with the observation that these cells already overexpress HSP70. Taken 
together, these findings demonstrate that the induction of HSP70 leads to a reduction in TLR4 
signaling and that the effects of HSP70 occur through an association between TLR4 and HSP70 
dependent upon EEVD domain in its C-terminus. Given the role of HSP70 in regulating the 
ubiquitin-mediated degradation of target proteins, we, therefore, next sought to investigate 
whether HSP70 associations with TLR4 could subsequently alter the ubiquitination state of 
TLR4 in enterocytes. 
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Figure 23. An EEVD-mediated association between TLR4 and HSP70 is required for the inhibition of TLR4
signaling in enterocytes by HSP70. (Ai) Representative SDS-PAGE showing lysates of IEC-6 enterocytes that had 
been virally transduced with either LacZ or HSP70 lacking the EEVD substrate-binding domain (ΔEEVD), prior to 
treatment with LPS, and maintained at 37 ̊C or treated at 42 ̊C for 45 min (heat) and then immunoprecipitated with
Abs to HSP70 and immunoblotted with anti-TLR4 Abs; shown is IgG as a loading control. (Aii) Quantitative RT-
PCR showing the expression of HSP70 in nontransfected control IEC-6 cells and IEC-6 cells that were transfected 
with full-length HSP70. Representative confocal photomicrographs of IEC-6 enterocytes that were either transduced 
with LacZ (Bi–iii, Ci–iii) or ΔEEVD-HSP70 (Biv–vi, Civ–vi) and then left untreated (Bi, Biv, Ci, Civ), treated with 
LPS (Bii, Bv, Cii, Cv), or treated with LPS plus pretreatment with heat (Biii, Bvi, Ciii, Cvi). Cells were then stained 
for NF-kB (green in B), or cleaved-caspase 3 (green), b-actin (red), and DAPI (blue) in (C). Scale bar, 10 mm. NF-
kB translocation (Bx) and percentage of apoptosis (Cvii) based upon >50 fields with >50 cells/field. *p<0.05, LPS 
open and solid bars versus control open and solid bar, **p <0.01, LPS+HS versus LPS open bar, ***p <0.001, 
control black bar versus LPS+HS black bar, ♦p <0.05, LPS black bar versus LPS open bar. Δ, no significant
difference between untreated, LPS-treated, or heat-exposed LPS-treated HSP70–IEC-6 cells. Summary of four 
separate experiments. (Bvii–ix) Confocal photomicrographs of IEC-6 cells that were transfected with HSP70 and 
treated as indicated. (Bxi) Quantitative RT-PCR showing IL-6 expression in IEC-6 cells that were transfected with 
LacZ or ΔEEVD and then treated with LPS as in Materials and Methods (6 h, 50 mg/ml). Representative 
apoptotic cells are indicated by arrows. *p<0.05, versus Ctrl, **p <0.01 versus LPS in LacZ-transfected cells. 
Representative of three separate experiments. Figure reprinted with permission from The American 
Association of Immunologists, Inc. Article: Copyright 2012 
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2.4.3 The	  induction	  of	  HSP70	  leads	  to	  ubiquitination	  and	  degradation	  of	  TLR4	  via	  
the	  co-­‐chaperone	  CHIP	  
In various cell types, HSP70 regulates the fate of target proteins, in part, by critically 
influencing their ubiquitination state and subsequent degradation through the proteasomal system 
(32). The degree of ubiquitination affected by HSP70 is directly influenced by the activity of a 
co-chaperone molecule CHIP, an E3-ligase bearing a ubiquitin ligase U-box domain and a 
HSP70-docking domain (33, 34). We now postulate that HSP70 induction limits TLR4 signaling 
by promoting its ubiquitination state via CHIP. To determine whether HSP70 induction affected 
TLR4 expression via effects on the extent of ubiquitination of TLR4, we first 
immunoprecipitated lysates of IEC-6 cells using anti-ubiquitin Abs in the absence or presence of 
heat and then performed SDS-PAGE using antibodies to TLR4. As shown in Fig. 24Ai, heat 
exposure increased the degree of TLR4 ubiquitination, which was associated with a reduction in 
TLR4 expression (Fig. 24Aii). Further evidence of the importance of HSP70 in regulating TLR4 
expression after heat treatment is shown in Fig. 24Aiii. After the administration of siRNA for 
HSP70, the expression of TLR4 was significantly greater, as detected by SDS-PAGE, than in 
wild-type cells that express HSP70 (see Fig. 22E for expression of HSP70 in the siRNA-treated 
cells, confirming knockdown of HSP70 by the siRNA approach). Importantly, heat treatment did 
not cause a reduction in TLR4 in IEC-6 cells after knockdown of HSP70, consistent with the 
important role of heat-induced HSP70 in mediating the regulation of TLR4 (Fig. 24Aiii), which 
is lost in these cells after HSP70 knockdown. Furthermore, the importance of ubiquitination in 
mediating the effects of HSP70 on TLR4 expression and signaling is demonstrated, because the 
treatment of IEC-6 cells with the proteasomal inhibitor MG-132 prevented the loss of TLR4 
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expression in response to heat while reversing the protective effects of heat shock on TLR4-
induced enterocyte apoptosis (Fig. 24B, 24C). To explore whether CHIP/HSP70-mediated 
interactions were required for the protective effects of HSP70 on TLR4 signaling and function 
via CHIP-mediated docking and ubiquitination of TLR4, we next introduced, via lentiviral-
mediated transduction, two dominant negative forms of CHIP into IEC-6 cells: H260Q, the E3-
ligase U-box mutant, which impairs the ability of HSP70/CHIP to polyubiquitinate target 
proteins, and K30A, a docking-domain mutant that impairs the ability of CHIP to interact with 
HSP70 and target proteins (267,414). We then assessed effects on protein stability, 
ubiquitination state, and TLR4 signaling. Introduction of the H260Q ubiquitin ligase mutant 
prevented the increase in the ubiquitination of TLR4 in response to heat exposure compared with 
IEC-6 cells that were infected with empty vector (LacZ; Fig. 24Ai) and significantly reduced the 
protective effects of heat exposure on LPS-mediated enterocyte apoptosis (Fig. 24B, 24D, 24E). 
Furthermore, transduction of IEC-6 cells with the K30A docking mutant also reversed the 
protection in LPS-induced enterocyte apoptosis that was previously provided from heat exposure 
(Fig. 24B, 24F). Taken together, these findings demonstrate that HSP70 limits TLR4 activation 
through ubiquitin-mediated protein degradation via CHIP. We next sought to determine whether 
TLR4 could limit its own signaling, in part through up-regulation of HSP70. Transduction 
controls are shown in Appendix Figure 31 where expression of the V5 tag is demonstrated in 
transduced cells 
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Figure 24.The induction of HSP70 leads to the ubiquitination and degradation of TLR4 via the co-chaperone
CHIP. (Ai) Representative immunoblots in which LacZ- and H260Q-transfected IEC-6 enterocytes were exposed to 
heat or were maintained at 37 ̊C and then immunoprecipitated with anti-ubiquitin Abs and immunoblotted with anti-
TLR4 Abs, displaying polyubiquitinated species (pUB-TLR4). The location of TLR4 on the gel is shown. (Aii) Rep- 
resentative SDS-PAGE of IEC-6 cells probed with anti-TLR4 Abs that were either nontransfected or transfected 
with H260Q and then maintained at 37 ̊C or exposed to heat, in which heat exposure leads to a reduction in TLR4
expression that is not seen in H260Q-transfected cells. (Aiii) SDS-PAGE showing expression of TLR4 and loading 
protein control in either wild-type (WT) IEC-6 cells or IEC-6 cells treated with siRNA to HSP70 (siHSP70) that 
were either untreated (Ctrl) or treated with heat as in Materials and Methods (Heat). (B) Percentage apoptosis per 
high-power field >50 fields with >50 cells/field. Representative confocal photomicrographs of IEC-6 enterocytes 
treated with MG-132 (C), or transduced with LacZ (D), H260Q-CHIP (E), or K30A-CHIP (F), treated as indicated, 
and immunostained with cleaved-caspase 3 (green), b-actin (red), and DAPI (blue). Arrows point to apoptotic cells. 
Scale bar, 10 mm. *p <0.05, control (all bars) versus LPS (all bars), **p <0.01, LPS (open bar) versus LPS+Heat 
(open bar) versus LPS open bar, ***p <0.001, Control versus LPS + Heat (black, red, and blue bars) in three 
separate experiments. Table reprinted with permission from The American Association of 
Immunologists, Inc. Article: Copyright 2012 
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2.4.4 TLR4	  induces	  HSP70	  expression,	  which	  then	  negatively	  affects	  TLR4	  signaling	  
During the inflammatory response, the activation of TLR4 in response to LPS must be 
carefully controlled; the failure to negatively regulate a TLR4 response would necessarily result 
in a pro-inflammatory cytokine storm each time a TLR4 signal was initiated. Having shown that 
HSP70 induction can inhibit TLR4 signaling in enterocytes, we next considered the possibility 
that TLR4 activation itself could also lead to an induction of HSP70, which could then serve to 
negatively regulate (and therefore to self-limit) TLR4 responsiveness. To do so, we first sought 
to evaluate the time dependency of the signaling response of TLR4 in IEC-6 cells using two 
separate techniques. IEC-6 cells were transiently transduced with an NF-kB–promoter driven 
GFP-reporter construct as a readout of TLR4 activation, treated with LPS, and assessed for the 
expression of GFP by confocal microscopy over time. Cells were also stained for HSP70 to 
assess its induction in response to LPS. Second, the induction of the pro-inflammatory molecule 
inducible NO synthase (iNOS) was assessed by RT-PCR over time after treatment with LPS. As 
shown in Fig. 25A (red staining) and Fig. 25B (solid bars), LPS caused a time-dependent 
signaling response in IEC-6 cells, which reached a maximum at 4–6 and then decreased by 16h. 
LPS also caused a time-dependent increase in the expression of HSP70 in IEC-6 cells (Fig. 25A–
C), which peaked at the time at which TLR4 signaling decreased (Fig. 25B, 25C). As a positive 
control for the effects of HSP70 on the confocal-based assay, heat exposure resulted in a marked 
inhibition of TLR4 signaling, as revealed by reduced GFP expression and an increase in HSP70 
expression (Fig. 25Aiv–vi). Of note, the effects of LPS and heat on the intracellular induction of 
HSP70 in IEC-6 cells is also shown in Fig. 25D.Several lines of evidence indicate that the 
intracellular increase in HSP70 expression that was observed to occur in response to LPS could 
limit TLR4 signaling. First, treatment of IEC-6 with the HSP70 inhibitor Quercetin resulted in an 
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increase in the extent of TLR4-induced IL-6 expression (Fig. 25Fi). Second, the increased 
expression of HSP70 that was noted in response to LPS resulted in an increase in the degree to 
which TLR4 could be detected in lysates of IEC-6 cells that had been immunoprecipitated with 
Abs to HSP70 (Fig. 25E), indicating that the increased HSP70 expression in response to TLR4 
activation also resulted in increased association of HSP70 with TLR4, consistent with the 
mechanism of action of HSP70 in reducing TLR4 signaling shown in Figs. 23 and 24. Third, 
inhibition of HSP70 using siRNA resulted in a marked exaggeration in the extent of TLR4 
signaling, as measured by an increase in both LPS-induced iNOS expression (Fig. 25Fii) and 
LPS-induced enterocyte apoptosis (Fig. 25Fiii) compared with control cells that had been 
transfected with control siRNA or no siRNA. Importantly, heat exposure did not prevent NF-kB 
translocation in IEC-6 cells that were treated with the TLR5 ligand flagellin, and these findings 
were not affected by the presence of Quercetin, suggesting that the effect of heat-induced TLR4 
suppression is specific for TLR4 signaling (Appendix fig 32). Taken together, these findings 
reveal that TLR4 can induce the expression of HSP70, which inhibits LPS signaling in 
enterocytes, and by extension, that HSP70 can exert a physiological role in constraining the 
effect of TLR4 signaling that occurs. Therefore, we next sought to investigate the role of HSP70 
on LPS-induced TLR4 signaling in vivo. 
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Figure 25. TLR4 induces HSP70 expression, which then negatively effects TLR4 signaling. (A) Representative
confocal photomicrographs of IEC-6 enterocytes transduced with GFP–NF-kB and then treated with LPS (t = 0) in 
the absence of heat (i–iii) or LPS after pretreatment with heat (iv–vi); cells were stained for HSP70 (red) and 
assessed for GFP (green) at the indicated time point. Scale bar, 10 mm. (B) Quantification of iNOS mRNA by RT-
PCR and HSP70 protein relative to b-actin. *p<0.05, versus t = 0 checkered bars, **p <0.01, 16h versus 8, 6 and 4h, 
checkered bars, ***p <0.001, t = 16 h versus other time points, solid bars. Data are representative of four separate 
experiments. (C) Representative SDS-PAGE showing HSP70 in IEC-6 cells treated with LPS. (D) Representative 
confocal photomicrographs of IEC-6 enterocytes under the indicated conditions and stained for HSP70 (green), b-
actin (red), and DAPI (blue). Scale bar, 10 um. (E) Representative SDS-PAGE of IEC-6 lysates treated with LPS, 
immunoprecipitated with anti-HSP70 Abs, and immunoblotted with TLR4 (upper bands) and HSP70. (Fi) Fold 
increase of IL-6 release by ELISA over media alone in IEC-6 cells treated as indicated. *p<0.05, solid bars versus 
open bars indicated point, ♦p <0.05, open bars versus 4-h time point. Representative of three separate experiments.
(Fii) iNOS RT- PCR in IEC-6 cells treated with LPS, as indicated. Representative of four separate experiments. 
(Fiii) Apoptosis in IEC-6 cells treated as indicated. Based upon four separate experiments with >50 
fields/experiment and >50 cells/field. *p<0.05, no siRNA solid versus open bars, **p <0.01, HSP70 siRNA versus 
no siRNA solid bars, ***p <0.001, versus HSP70 siRNA versus control siRNA, solid bars. Figure reprinted 
with permission from The American Association of Immunologists, Inc. Article: Copyright 2012 
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2.4.5 HSP70	  negatively	  regulates	  TLR4	  signaling	  in	  the	  intestinal	  epithelium	  
The systemic administration of LPS to newborn mice is known to cause a significant 
inflammatory response in the small intestine that includes an increase in the expression of iNOS 
and an induction in enterocyte apoptosis (178,415,416). Based upon the above findings, in which 
HSP70 was found to inhibit enterocyte TLR4 in vitro, we next sought to evaluate the effects of 
HSP70 on enterocyte TLR4 signaling in vivo. To do so, we injected saline or LPS into wild-type 
mice or into two additional mouse strains: mice that were globally deficient in HSP70 (HSP70-/-) 
and mice that selectively overexpress HSP70 within the intestinal epithelium (HSP70villin). As 
shown in Fig. 26A, the injection of LPS into wild-type mice caused a time-dependent increase in 
the mucosal expression of iNOS, as well as a significant induction in enterocyte apoptosis (Fig. 
26Bi, 26Bii, 26C). In contrast, injection of LPS into mice that selectively overexpress HSP70 
within the intestinal epithelium resulted in a marked reduction in LPS-mediated iNOS expression 
within the intestinal epithelium compared with wild-type mice (Fig. 26A) and a reduction in 
enterocyte apoptosis (Fig. 26Biii, 26Biv, 26C), demonstrating that HSP70 could negatively 
regulate TLR4 signaling in vivo and supporting the in vitro data shown in Fig. 25. Moreover, the 
injection of LPS into HSP70-/- mice resulted in a significantly increased degree of apoptosis 
compared with LPS-injected wild-type mice (Fig. 26Bv, 26Bvi, 26H), providing further 
evidence that HSP70 negatively regulates TLR4 signaling in vivo. Therefore, we next sought to 
determine the physiological relevance of these findings in the pathogenesis of NEC. 
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Figure 26.HSP70 negatively regulates TLR4 signaling in the intestinal epithelium. (A) RT-PCR for iNOS in the
intestinal epithelium in wild-type or HSP70villin mice treated with LPS for the time points indicated. *p<0.05, red bar 
versus open bar for each point indicated. (B) Confocal photomicrographs of newborn intestine obtained from the 
terminal ileum after injection with saline (Bi, Biii, Bv) or LPS (5 mg/kg, 16 h; Bii, Biv, Bvi) in wild-type (Bi, Bii), 
HSP70villin (Biii, Biv), or HSP70-/-(Bv, Bvi) mice. Original magnification 340. (C) Quantification of apoptosis in
the small intestine of newborn mice, as in (B), after injection with saline or LPS, as indicated. Based upon four 
separate experiments with more than four mice/group and >50 fields examined per group. *p<0.05, saline versus 
LPS for open and black bars, **p <0.01, LPS white bar versus LPS solid bar, ***p <0.001, LPS red bar versus LPS 
solid bar. *Saline-treated black bar versus open bar or red bar. Figure reprinted with permission from The 
American Association of Immunologists, Inc. Article: Copyright 2012 
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2.4.6 HSP70	  signaling	  negatively	  regulates	  the	  development	  of	  NEC
We and other investigators demonstrated that NEC is a disease characterized by TLR4-
mediated apoptosis within the newborn small intestine (155,156,407). Having now shown that 
HSP70 can limit TLR4 signaling in enterocytes both in vivo and in vitro, we next sought to 
evaluate whether a lack of HSP70 may lead to an increase in the severity of NEC. As shown in 
Fig. 27A, the expression of HSP70 in both mice (Fig. 27Ai, 27Aii) and humans (Fig. 27Aiii, 
27Aiv) with NEC was significantly decreased compared with control bowel, indicating the 
possibility that disturbances of HSP70 expression or function may play a role in NEC 
development. To investigate directly whether HSP70 could regulate the development of this 
disease, NEC was induced in wild-type, HSP70-/-, and HSP70villin mice using a combination of 
formula gavage and intermittent hypoxia. As shown in Fig. 27B, the induction of NEC in wild-
type mice resulted in enterocyte apoptosis (Fig. 27B, 27Bii, 27Ei), mucosal disruption (Fig. 
27Biii, 27Biv), and an increase in the expression of iNOS in the intestinal mucosa (Fig. 27Eii). 
Importantly, the induction of NEC in HSP70-/- mice showed a significant increase in the extent of 
enterocyte apoptosis (Fig. 27Ci, 26Cii, 26Ei), mucosal disruption (Fig. 27Ciii, 27Civ), and 
iNOS expression (Fig. 27Eii), as well as increased disease severity (Fig. 27Eiii), whereas the 
induction of NEC in the HSP70villin mouse that overexpresses HSP70 in the intestinal epithelium 
resulted in a marked reduction in each of these measures (Fig. 27D, 27E). Taken together, these 
findings illustrate that HSP70 plays a key role in the regulation of NEC. We next sought to 
evaluate whether pharmacologic induction of HSP70 could inhibit TLR4 signaling and affect 
NEC severity. 
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Figure 27.HSP70 signaling negatively regulates the development of NEC. (Ai) RT-PCR showing HSP70 on each
day of the 4d NEC model. *p<0.05, versus day 0, *p <0.01, versus day 1. Representative of more than four separate 
experiments (n = 10 mice/group). (Aii) Representative confocal photomicrographs showing the expression of HSP70 
(red) and DAPI (blue) in the terminal ileum of mice without (Control) and with NEC (NEC). (Aiii) PCR showing the 
expression of HSP70 in intestine from infants without (open bar) and with NEC (solid bar). *p<0.05, solid versus 
open, based upon nine separate samples/group. (Aiv) Representative SDS- PAGE from infant without (Ctrl) and 
with NEC blotted with Abs to HSP70 and then probed for Hsc70 and b-actin. Representative confocal and H&E 
photomicrographs of sections of the terminal ileum from wild-type (B), HSP70-/-(C), or HSP70villin (D) newborn
mice with or without NEC. In (Bi, Bii), (Ci, Cii), and (Di, Dii), slides were stained for cleaved-caspase 3 (red) and 
DAPI (blue). Scale bar, 250 μm. (Ei) Apoptosis. (Eii) iNOS RT-PCR in the terminal ileum. (Eiii) NEC severity. 
Based upon at least four experiments with >15 mice/strain/group. *p<0.05, NEC in wild-type versus control, **p 
<0.01, NEC in HSP70-/-versus wild-type, ***NEC in HSP70villin versus wild-type and HSP70-/-. Figure reprinted 
with permission from The American Association of Immunologists, Inc. Article: Copyright 2012 
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2.4.7 Pharmacologic	  induction	  of	  HSP70	  limits	  TLR4	  signaling	  in	  enterocytes	  in	  vitro	  
and	  in	  vivo,	  and	  attenuates	  the	  severity	  of	  experimental	  necrotizing	  
enterocolitis	  
In the final series of studies, we sought to evaluate whether the pharmacologic induction of 
HSP70 could inhibit TLR4 signaling in vitro and in vivo and, thus, attenuate the severity of NEC. 
To do so, we used the small molecule Celastrol (320,321), a novel cell-permeable triterpenoid 
antioxidant that was shown to induce HSP70 expression and activity in a variety of cells 
(417,418). As shown in Fig. 28Ai, treatment of IEC-6 cells with Celastrol led to a rapid 
induction of HSP70, as determined by SDS-PAGE. In parallel, the injection of Celastrol into 
mice on three consecutive days resulted in an increase in the expression of HSP70 within the 
intestinal mucosa on each day (Fig. 28Aii). Importantly, the exposure of IEC-6 cells to Celastrol 
resulted in a marked increase in cytoplasmic HSP70 expression (red staining in Fig. 28Bi–iv), 
as well as a significant reduction in the extent of TLR4 signaling, as measured by a reduction in 
the extent of LPS-induced apoptosis (Fig. 28Biv versus Fig. 28Bii, 28Ei), a reduction in the 
extent of LPS-induced NF-kB translocation (Fig. 28C, 28Eii), and a significant reduction in the 
extent of LPS-induced IL-6 expression (Fig. 28Eiii). There were no effects of Celastrol 
treatment alone on enterocyte apoptosis, NF-kB translocation, or IL-6 expression (Fig. 28Biii, 
28Ciii, 28Ei). Having shown that the injection of Celastrol into mice can induce HSP70 
expression within the intestinal mucosa (Fig. 28Aii), we next sought to determine whether 
Celastrol could inhibit TLR4 signaling in the intestinal epithelium via effects on HSP70 
induction. To do so, wild-type and HSP70-/- mice were injected with Celastrol 24h prior to LPS 
and then assessed for the extent of enterocyte apoptosis and iNOS expression in the intestinal 
mucosa. As shown in Fig. 28Di-iv and 28Fi, the administration of Celastrol to wild-type mice 
led to a significant reduction in the extent of LPS-induced enterocyte apoptosis compared with 
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the effects of LPS in wild-type mice that did not receive Celastrol, as well as to a significant 
reduction in the extent of LPS-induced expression of iNOS in the intestinal mucosa compared 
with wild-type mice (Fig. 28Fii). Importantly, there was no protective benefit of Celastrol when 
it was administered to HSP70-/-mice, confirming that its protective effects required HSP70 
induction (Fig. 28Dv–viii, 28F). The specificity of Celastrol for TLR4-mediated enterocyte 
apoptosis was confirmed in vitro. Although LPS caused a significant increase in enterocyte 
apoptosis in HSP70-deficient IEC-6 cells, the addition of Celastrol did not confer protection; in 
fact, these HSP70-deficient enterocytes were significantly more susceptible to apoptosis than 
were their nontransfected counterparts (Appendix Fig. 33). 
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Figure 28.Pharmacologic induction of HSP70 limits TLR4 signaling in IECs in vitro and in vivo. (Ai)
Representative SDS-PAGE of IEC-6 enterocytes treated with Celastrol or DMSO and blotted with HSP70 and then 
reprobed for b-actin. (Aii) Representative SDS-PAGE of mucosal scrapings from terminal ileum of newborn mice 
administered Celastrol daily for 3d. Representative confocal photomicrographs of IEC-6 enterocytes treated as 
indicated and immunostained for HSP70 [red in (B)] and DAPI [blue in (B)] or NF-kB [green in (C)] and b-actin 
[red in (C)].Representative apoptotic cells are indicated by arrows. Scale bar, 10 um. Representative confocal 
photomicrographs of terminal ileum in newborn wild-type (Di–iv) or HSP70-/-(Dv–viii) mice that were treated, as
indicated, and stained for cleaved-caspase 3 (green), DAPI (blue), and b-actin (red). Scale bar, 250 um. (E) Quan- 
tification of apoptosis, p65 translocation, and IL-6 mRNA expression in IEC-6 cells. *p<0.05, control versus LPS 
open bars, **LPS open bars versus LPS+ Celastrol closed bars in four separate experiments. Quantification of 
apoptosis (Fi) and iNOS expression (Fii) by RT-PCR in the terminal ileum of newborn wild-type or HSP70-/-mice.
Representative of four separate experiments, with >10 mice/group. *p<0.05, open bars LPS versus control, 
**p<0.01, LPS+Celastrol versus LPS open bars. Figure reprinted with permission from The American 
Association of Immunologists, Inc. Article: Copyright 2012 
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Based upon the above findings, we next sought to evaluate whether the induction of HSP70 
that occurs with the administration of Celastrol could attenuate the severity of experimental 
NEC. To test this directly, we first administered either DMSO or Celastrol by i.p. injection to 
newborn pups on days 0 and 1 of the experimental model and assessed the effects on extent of 
mucosal disruption, enterocyte apoptosis, induction of iNOS, and disease severity. As shown in 
Fig. 29, the administration of Celastrol markedly reduced the degree of mucosal disruption (Fig. 
29Ai–iii), enterocyte apoptosis (Fig. 29Av–vii, 29Ci), mucosal iNOS expression (Fig. 29Cii), 
and disease severity (Fig. 29Ciii) compared with mice that had been administered DMSO. It is 
noteworthy that the injection of Celastrol resulted in a marked increase in the expression of 
HSP70 and a reduction in TLR4 compared with mice with NEC that received DMSO alone, 
consistent with the mechanism of action for Celastrol shown in Fig. 28. Having shown that the 
induction of HSP70 through the administration of Celastrol could prevent the development of 
NEC when administered prior to the start of the model, we next sought to determine whether 
Celastrol administration could reduce the severity of NEC once the disease had been established 
in mice. To do so, we injected mice with Celastrol on the last 2d of the 4d model, at a time in 
which significant inflammation is already established. Strikingly, as shown in Fig. 29, mice with 
NEC that received Celastrol after disease induction showed restoration of mucosal architecture 
(Fig. 29Aiv), a significant reduction in enterocyte apoptosis (Fig. 29Aviii, 29Ci), and a reduction 
in NEC severity (Fig. 29Ciii), all to levels that were similar to mice without NEC and 
comparable to levels observed in mice receiving Celastrol as a prevention strategy (checkered vs 
solid bars in Fig. 29C). Taken together, these findings suggest that the pharmaceutical induction 
of HSP70 may be used as a novel approach to the prevention or treatment of NEC through 
effects on the inhibition of TLR4 signaling in the newborn small intestine. 
100 
Figure 29. Pharmacologic induction of HSP70 prevents and also treats experimental NEC in mice. Representative
H&E (Ai–iv) and confocal images [(Av–viii), cleaved-caspase 3 (green), b-actin (red), DAPI (blue)] of sections from 
terminal ileum of newborn mice that were either breastfed [Control, (Ai) and (Av)] or induced to develop NEC and 
administered either DMSO [(Aii) and (Avi)] or 1 mg/kg Celastrol on days 0 and 1 of the 4d model [(Aiii) and (Avii)]. 
In parallel, mice that had NEC for 2d were administered 1 mg/kg Celastrol for 2d [(Aiv) and (Aviii)]. Scale bar, 250 
um. (B) SDS-PAGE of mucosal scrapings from mice subjected to experimental NEC and injected with either 
DMSO or Celastrol on the first 2d of the model; blots were probed for HSP70 and then stripped and reprobed for 
TLR4 and b-actin. Quantification of enterocyte apoptosis (Ci), iNOS by RT-PCR in the terminal ileum (Cii), and 
NEC severity (Ciii).Representative of four separate experiments with >10 mice/group. *p<0.05, NEC Ctrl (solid bar) 
versus control (open bar), **p <0.01, NEC Celastrol – prevention (solid bar) versus NEC Ctrl – prevention (solid 
bar), ***p <0.001, NEC Celastrol treatment (checkered bar) versus NEC control (solid bar). Figure reprinted 
with permission from The American Association of Immunologists, Inc. Article: Copyright 2012 
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3.0	   DISCUSSION	  
We now define a novel mechanism by which TLR4 is regulated in the newborn intestinal 
epithelium that has important implications in the pathogenesis of NEC, a disease that is 
characterized by exaggerated TLR4 signaling within the intestinal mucosa (155,156,159). 
Specifically, we identify that the induction of HSP70 leads to a reduction in TLR4-induced 
signaling in enterocytes, as measured by a reduction in NF-kB activation, cytokine induction, 
and apoptosis, and that induction of HSP70 either pharmacologically or genetically leads to a 
reduction in TLR4 signaling and a marked inhibition in the severity of NEC. The current results 
identify a novel pathway that links cytoplasmic HSP70 induction with TLR4 regulation and 
demonstrate that impaired HSP70 expression or function may, in part, underlie the causes of this 
devastating disease. These findings represent a novel departure from current thinking in the field 
by revealing that future treatments for NEC may involve nonspecific immunological approaches, 
such as the elimination of microbial pathogens or the administration of particular feeding 
regimens (419), as well as the pharmacologic induction of an intracellular chaperone, such as 
HSP70, to limit disease progression through inhibitory effects on the innate immune receptor 
TLR4. 
An important finding of the current study involves the proposed mechanism of action of 
HSP70 in limiting TLR4 signaling within enterocytes. As a molecular chaperone, HSP70 can 
associate with co-chaperone proteins through an EEVD motif in its C-terminus (411,412). As 
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shown in Fig. 23, we now demonstrate that the inhibition of TLR4 signaling in response to 
HSP70 induction required this EEVD-binding motif (266), because the introduction of a mutant 
lacking this domain prevented the association between TLR4 and HSP70, presumably via a co-
chaperone intermediary, as well as reversed the protection of HSP70 induction on TLR4 
signaling (Fig. 23). This mechanism of action for HSP70 is in agreement with recent work of 
Chow et al. (420), who showed that HSP70 mutants with a functional EEVD motif but lacking 
N-terminus ATPase activity were still capable of protecting L929 fibroblasts from apoptosis 
induced by pro-inflammatory cytokines. 
We also determined that the association between HSP70 and TLR4 results in enhanced 
ubiquitination and degradation of TLR4, a process that we have now determined to require the 
co-chaperone and E3 ligase CHIP (Fig. 24). CHIP has not previously been linked to TLR4 
signaling within the intestinal epithelium, and we further reveal that mutations in both its 
docking (K30A) or ubiquitination U-Box domain (H260Q) prevented the protective effects of 
HSP70 induction on TLR4. These findings define the mechanism by which CHIP may act to 
mediate the inhibitory effects of HSP70 on TLR4 signaling and are in agreement with the known 
function of CHIP in regulating the activity of other HSP70 targets through ubiquitination 
(421,422), yet to our knowledge, they represent the first direct link of CHIP to an intestinal 
inflammatory disease. It is noteworthy that in the original description of the CHIP-deficient 
mouse, attention was drawn to the intestinal phenotype that was observed when mice were 
subjected to a brief hyperthermic stress, characterized by friability of the small intestine with 
marked apoptosis of the intestinal epithelium (423), although potential CHIP targets that could 
mediate this effect on the small intestine during stress were not identified. It is tempting to now 
speculate that CHIP may play a central role in the maintenance of intestinal homeostasis, in part 
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by preventing the unbridled activation of immune targets of CHIP, such as TLR4 in such settings 
as NEC. 
It should be noted that the current findings in which cytoplasmic HSP70 serves to curtail 
the signaling of TLR4 within the intestinal epithelium lie in distinction to a growing and 
somewhat controversial body of work concerning the extracellular role of HSP70 and other heat 
shock proteins in activating the innate immune system via TLR4 (348,424-428). In this regard, 
Retzlaff et. al. (429) showed that the exogenous administration of HSP70 could increase IL-1, 
IL-6, and TNF in cultured macrophages, whereas Wheeler et. al. (430) showed that the 
extracellular exposure of HSP70 to neutrophils from wild-type mice leads to the release of IL-8, 
yet this effect is not observed in neutrophils from C3H/HeJ mice that have inhibitory mutations 
in TLR4. Although very exciting, such studies were recently called into question by concerns 
that the observed effects might actually result not from the heat shock proteins themselves, but 
rather from contaminants, such as LPS, which could inadvertently be present within the protein 
preparations or be bound specifically to the heat shock proteins (56). For example, Wallin et. al. 
(431), Bausinger et al. (432), and Gao and Tsan (433) showed that the activation of immune cells 
previously attributed to HSP70 were lost when highly purified recombinant proteins were used, 
although these results were recently and convincingly rebutted in two review articles on this 
topic (434,435).  In contrast to studies in the field of extracellular HSP70 biology, the novelty 
and importance of the current findings lie in the newly discovered link between TLR4 and 
HSP70 within the enterocyte both in vitro and in vivo, as well as the potential etiological 
relevance to the development of NEC. And although they represent an extension of the classic 
role of HSP70 in modulating the fate of cytoplasmic proteins, the relevance, if any, to the body 
of literature surrounding the fate of HSP70 outside of the cells is unknown. 
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Other diseases of intestinal inflammation, including ulcerative colitis and Crohn’s disease, 
in which TLR4 signaling may play a lesser, or perhaps even opposite, role make integrating the 
current work complex. Although we (155,159) and other investigators (156,163) showed that the 
development of NEC requires TLR4 activation, it was shown that TLR4 plays a protective role 
in experimental colitis (133,436). Several reasons may account for this apparent discrepancy that 
have relevance to the current study. TLR4 activation leads to intestinal injury in a well-defined 
and physiologically relevant context (i.e., the newborn small intestine). In support of this 
concept, we recently demonstrated that TLR4 activation with LPS leads to increased enterocyte 
apoptosis in the terminal ileum of newborn mice but not adult mice, as well as in the small 
intestine but not the newborn colon (158). Further, reports that demonstrate a protective role for 
TLR4 in models of colitis have typically been based upon the use of global TLR4 knockout 
mice, in which TLR4 signaling is disrupted in enterocytes as well as T cells and myeloid cells. 
We recently showed that TLR4 signaling within the enterocyte itself is important for the 
induction of intestinal injury leading to NEC, using enterally administered adenoviral constructs 
that bear inhibitory mutations in TLR4 whose expression is largely favored within the small 
bowel mucosa (113,159) and also in enterocyte specific TLR4 conditional knockout mice (70). 
Therefore, it is reasonable to conclude that the protective effects attributed to TLR4 signaling in 
the gut by previous investigators may reflect, in part, the mitigating effects of TLR4 signaling on 
other cells. In support of this possibility, we note that Fukata et al. (437) recently showed, in an 
elegant study using chimeric mice, that TLR4 signaling in colonic epithelial cells worsened 
intestinal inflammation. These findings argue that the effects of TLR4 in the development of 
intestinal inflammation are strongly influenced by a variety of factors, including the effector cells 
involved, developmental factors, and involved region of the intestine. The precise effects of 
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HSP70 at these varying stages of development and within these different cell types remain to be 
explored in further detail, but they are likely to provide important clues to the underlying causes 
of these diseases. 
It is important to note that the current findings do not represent the sole HSP70-dependent 
mechanism in play to curb IECs injury and inflammation associated with exaggerated TLR4 
signaling. Recent work by Chen et.al. (438) illustrates HSP70 can also block the ubiquitination 
and activation of TRAF6 via direct binding in macrophages. Interestingly, this interaction is 
dependent upon the C-terminus of HSP70 consistent with our work illustrating a dependence 
upon the C-terminal EEVD motif of HSP70 for the inhibition of NF-kB activation and apoptosis. 
Additionally, previous work has demonstrated that HSP70 can negatively regulate NF-kB 
activation. Ran et. al. (84) demonstrate that HSP70 directly interacts with the IKKγ subunit of 
the IKK complex  preventing the oligomerization of IKKγ proteins and formation of the IKK 
complex upon HSR activation. While HSP90 functions to stabilize the IKK complex playing an 
important role in NF-kB activation (85), the presence of HSP70 in the IKK complex has been 
shown to disturb its function and IkBα phosphorylation and ubiquitination (89). Other studies 
have illustrated that HSF1 activation and nuclear translocation can lead to inhibition of NF-kB 
DNA binding directly (90). Although this mechanism may play a lesser role in the current 
studies as we have found induction of HSP70 in IEC6 leads to inhibition of NF-kB nuclear 
translocation. 
While not directly addressed in this work, DAMP release may play an important casual 
role in NEC. Recent work in the Hackam lab has demonstrated that HMGB1 expression is 
significantly increased in both murine and human NEC. HMGB1 was demonstrated to inhibit 
enterocyte migration via TLR4 activation both in vitro and in vivo. Interestingly, this was unique 
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to enterocytes as inflammatory cell migration was significantly enhanced following exposure to 
HMGB1 (105). Work by Tang et. al. (106,108) has demonstrated that the induction of HSP70 
can lead to translocation to the nucleus where stress-induced HMGB1 release by macrophages 
can be significantly attenuated. It stands to reason, therefore, that over-expression of HSP70 in 
enterocytes, or gut immune cells, may lead to decreased HMGB1 release in the setting of 
intestinal inflammation. HSR activation in vitro or in vivo may directly inhibit HMGB1 or other 
DAMP release in the setting of NEC further attenuating the severity of this disorder. 
The cytoprotective mechanisms of HSP70 extensively studied and summarized above 
involve multiple intersection points along different apoptotic (intrinsic vs extrinsic and caspase-
dependent vs caspase-independent) and apoptotic-like pathways. The current work demonstrates 
a significant attenuation in TLR4-mediated enterocyte apoptosis via HSP70 up-regulation and 
correlates this to a significant attenuation in NEC severity. HSP70 activity leads to an inhibition 
of Caspase 3 activation consistently seen in NEC. While in the current work this is correlated to 
attenuation in caspase-dependent apoptosis, further studies are necessary to determine the exact 
mechanism of apoptosis prevention, e.g. inhibition of APAF1-Cytochrome c-Caspase 9 
apoptosome formation. These studies also do not rule out the possibility of other mechanisms of 
HSP70-mediated cytoprotection against caspase-independent apoptosis, e.g. inhibition of AIF 
activity. The role of apoptosis-like cell death pathways such as pyroptosis or necroptosis in the 
setting of NEC have yet to be elucidated. Caspase 1 via inflammasome formation and death 
receptor caspase 8 activity via kinases RIP1 or RIP3 which play key initiating roles in pyroptosis 
(107) and necroptosis (110), respectively, have been demonstrated to be regulated via HSP 
activity as described previously or via inhibition of downstream effectors (109) (382). Further 
work is necessary to not only determine the role of these apoptotic-like cell death pathways in 
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NEC as well as the role HSP70 induction may play in modulating these pathways in protecting 
the newborn gut from this disorder. 
Based upon the current findings, we now propose a model by which HSP70 limits TLR4 
signaling and plays a key role in influencing the development of enterocyte apoptosis and the 
development of NEC (Fig. 30). Under healthy conditions, the relationship between the 
indigenous flora of the host and the baseline activation of TLR4 exists in homeostatic balance, 
which we now attribute, in part, to a constitutive role of HSP70 in limiting the extent of TLR4 
signaling by controlling its degradation through proteasomal pathways. The interaction between 
TLR4 and HSP70 may occur within intracellular compartments, such as the Golgi apparatus, 
where TLR4 signaling was shown to reside primarily and occur within the enterocyte (101). In 
contrast, under the conditions of stress that favor the development of NEC (increased LPS, 
hypoxia, and prematurity), the exhaustion of HSP70 signaling, accompanied by the relative 
increase in TLR4 expression in the preterm gut (113), leads to exaggerated TLR4 activation and 
the development of the increased enterocyte apoptosis and pro-inflammatory cytokine expression 
in the newborn intestine that leads to NEC. It is also notable that the pharmacologic induction of 
HSP70 can curtail TLR4 signaling and both prevent and treat experimental NEC. 
These data present a novel pathway by which HSP70 serves to limit TLR4 signaling in the 
intestinal epithelium, and moreover, shows that factors that increase HSP70 signaling can 
attenuate NEC severity through inhibition of TLR4. We believe that such findings offer new 
insights into the molecular requirements that lead to NEC development, as well as offer novel 
therapeutic approaches for this devastating disease. It is important to note that while our studies 
demonstrate a significant protective effect of Celastrol in experimental NEC, this particular drug 
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Figure 30. Proposed model: HSP70 regulates TLR4 signaling in enterocytes in the pathogenesis of NEC. As described in the text,
under healthy conditions. TLR4 is activated by host microbes. The degree of activation is limited by HSP70 through effects on 
TLR4 degradation through proteasomal pathways via CHIP. In contrast, under the conditions of stress that favor the development 
of NEC, the reduction in HSP70 expression accompanied by the increase in TLR4 expression leads to exaggerated TLR4 
activation and the development of increased enterocyte apoptosis and pro-inflammatory cytokine expression in the newborn 
intestine. This leads to the development of NEC. Moreover, pharmacologic induction of HSP70 can curtail TLR4 signaling and 
both prevent and treat experimental NEC. Figure reprinted with permission from The American 
Association of Immunologists, Inc. Article: Copyright 2012
maintains a very narrow therapeutic dose window. Due to the significant toxicity of Celastrol, it 
is unlikely to translate directly to clinical trials. We have used this specific drug due to its wide 
availability and as a proof of concept that pharmacologic inducers of HSP70 may provide novel 
treatments for NEC. However, these treatment options will not be without their side effects. A 
major concern for the use of HSP70 inducers is the possibility of malignancies arising due to 
prolonged pharmacologic expression of HSP70 in tissues. These treatments will undoubtedly 
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require strict monitoring and tailoring for use in diseases like NEC.  As NEC does not develop in 
all preterm infants and rarely manifests in term infants, a major challenge in the field is the 
elucidation of novel biomarkers or polymorphisms that may shed light on which infants are at 
risk. The data we present suggest the possibility that certain polymorphisms that may effect 
HSP70 expression or function could predispose to NEC development. Polymorphisms altering 
CHIP or HSF expression or activity may also predispose to this disease. Given the critical role of 
TLR4 in the pathogenesis of NEC, polymorphisms leading to increased TLR4 expression or 
activity may also predispose infants to NEC. Identifying such markers as well as clinical 
biomarkers would undoubtedly drastically alter our current approaches to NEC patients and thus 
patient outcomes.     
While the mechanisms at play involving HSP70-mediated cytoprotective effects have 
been well studied, the mechanisms governing TLR4-mediated apoptosis are less well 
characterized. The current work demonstrating a novel mechanism of how activation of the HSR 
and a stress-induced molecular chaperone can curb the injurious effects of an innate immune 
receptor sheds light upon a possible pathway leading to TLR4-mediated cell death. As touched 
upon briefly above, the HSR and UPR play key cytoprotective roles in proteostasis. The small 
bowel is a highly secretory organ as evident by the amount of mucus, AMPs, IgA and hormones 
produced daily. It is therefore unsurprising that proteostasis and those mechanisms in place 
which maintain this balance, such as the UPR, are especially critical in the intestine. The 
intestinal parenchyma is taxed with the mass production and secretion of these products and 
subsequently maintains a very high demand and reliance upon translational and protein-folding 
machinery and proteostasis pathways. It is due to this that the intestine remains an organ with a 
relatively high baseline of ER stress (115). 
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ER stress refers to a state of cellular stress that culminates in the accumulation of 
unfolded proteins within the ER, which can be transient and well-controlled or insurmountable. 
It has been shown that during conditions of cell stress, such as hypoxia as well as during 
inflammatory conditions leading to increased cytokine synthesis, the protein load in the ER 
exceeds the capacity for normal folding (112). This accumulation of misfolded/unfolded proteins 
in the ER leads to the induction of the UPR. Similar to the HSR induction in response to 
cytoplasmic disturbances in proteostasis, the UPR encompasses signaling pathways aimed at 
relieving ER protein burdens. If the activation of the UPR is unable to correct this accumulation, 
prolonged ER stress and by extension prolonged UPR activation will result in apoptosis (112). A 
key sensor and upstream modulator of the UPR is the resident ER chaperone and HSP70 family 
member, BiP also referred to as GRP78. BiP plays a key role in the proper folding of nascent 
peptide chains newly translated and released into the ER from bound ribosomes. Under 
conditions of ER proteostasis, BiP is found primarily in complex with three resident proteins in 
the ER: ATF6, PERK and IRE1 (112). These proteins comprise the three arms of the UPR 
signaling cascade. While in complex with BiP, each arm of the UPR remains in an inhibitory 
state. Upon accumulation of unfolded nascent peptides, BiP dissociates from its bound state to 
fold/refold these proteins leaving each of the three arms of the UPR free for activation. ATF6 
activation leads to its cleavage and translocation to the nucleus where it transcribes target genes 
aimed at increasing ER size and protein folding machinery including, among other resident 
chaperones, BiP (112). PERK activation results in autophosphorylation as well as the 
phosphorylation of the important translation initiation factor 2α (eIF2α), indirectly inactivating 
eIF2 and decreasing mRNA translation. This leads to a sharp decrease in translation and leads to 
the preferential induction of the transcription factor ATF4 and subsequent transcription and 
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translation of its critical gene target CHOP, a transcription factor controlling expression of pro-
apoptotic genes. Activation of the PERK pathway is therefore a significantly protective arm of 
the UPR at modest levels of activation or detrimental at exaggerated ER stress levels or 
prolonged amounts of time. IRE1 is both a kinase and endoribonuclease. UPR activation results 
in the splicing of UPR-specific transcription factor Xbp1 mRNA giving rise to Xbp1(s).  Xbp1(s) 
target genes result in increases in ER capacity, protein folding machinery and ER-associated 
degradation components. IRE1 activation also decreases ER protein load by directly degrading 
ER bound mRNA transcripts. The IRE1 and ATF6 arms of the UPR are generally viewed as the 
adaptive arms primarily activating pathways aimed at relieving ER burden. The key switch 
between UPR activation as a means to maintain homeostasis vs leading to the cell’s demise 
centers upon its timely resolution. If ER stress is prolonged, sustained PERK activity leads to 
CHOP-mediated apoptosis of the dysfunctional cell (112). 
In a seminal paper by Kaser et. al. (116) mice lacking Xbp1 expression in the intestinal 
epithelium demonstrated significant intestinal injury and inflammation as measured by increased 
susceptibility to experimental colitis. These animals also demonstrated a spontaneous enteritis 
following Xbp1 removal and subsequently defective UPR. Given the importance of a functional 
intestinal UPR in modulating intestinal inflammation and injury, it is tempting to hypothesize 
that these pathways are also critical in the setting of NEC. The current work demonstrates that 
TLR4, a fundamental player in the pathogenesis of NEC, is inhibited by the molecular chaperone 
HSP70. With the high physiologic baseline of ER stress within the gut, it may be that the gut is 
uniquely susceptible to acute increases in ER stress tipping the balance toward injury from 
homeostasis. Therefore, a potentially fruitful avenue of NEC research may center on the 
investigation of the role of exaggerated TLR4 signaling in inducing ER stress in the newborn 
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intestinal epithelium leading to intestinal inflammation, apoptosis and subsequently NEC. This 
would involve the specific elucidation of which specific UPR pathways are activated in response 
to TLR4 activation and determining whether manipulation of these pathways can alleviate 
disease severity. We will seek to determine if enterocyte TLR4 activation induces markers of ER 
stress both in vitro and in vivo and in the setting of NEC both murine and human. Generation of 
cell lines and utilization of animals deficient in the various UPR pathways described above will 
aid in the delineation of key pathways involved in modulating or inducing TLR4-mediated 
injury. Utilization of TLR4 mutant animals, which are known to be protected from intestinal 
injury and NEC development would be expected to also demonstrate a significantly attenuated 
amount of ER stress markers compared with wild-type animals. We hypothesize that exaggerated 
TLR4-mediated ER stress will lead to intestinal injury via prolonged PERK/CHOP pathway 
activation and specific targeting of these pathways, via deficient cells/mice or pharmacologic 
inhibition via Salubrinal, would prevent or alleviate TLR4-mediated injury. Given the current 
work, we would also hypothesize that overexpression of HSP70 family members would also 
demonstrate decreased ER-stress markers in the face of TLR4 activation both in vitro and in 
vivo, e.g. in HSP70villin animals exposed to the NEC model.  In line with Kaser et. al. we would 
also hypothesize Xbp1 via IRE1 activity plays an important role in modulating TLR4-mediated 
ER stress and that mice deficient in this pathway would display exaggerated intestinal injury in 
NEC. We have previously demonstrated that the expression of TLR4 is significantly increased in 
the preterm murine pup and in the preterm human and that this exaggerated expression 
predisposes to excessive signaling and NEC (113). Similarly, the preterm infant may display 
markers of exaggerated ER stress, possibly directly due to TLR4 expression, may predispose to 
intestinal injury upon colonization and TLR4 activation. Assessment of the ontogeny of ER 
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stress markers in both wild-type and TLR4 mutant animals may shed light on this. Our lab has 
previously utilized in utero injection of murine embryos to test intestinal biology (113)(117). 
Utilizing this technology, specific targeted knockdown of UPR pathways, e.g. PERK, via 
lentiviral shRNA introduction and transduction, may enable the specific blockade of detrimental 
ER stress pathways prior to NEC model exposure. Determination of the specific mechanism(s) 
governing TLR4-mediated ER stress would undoubtedly also serve as therapeutic avenues for 
novel NEC treatments and insights into potentially novel NEC etiologies. Possible mechanisms 
include excessive TLR4-mediated protein synthesis and release (e.g. cytokines) that over burden 
ER capacity. TLR4-mediated ROS generation is also a possible mechanism for induction of 
enterocyte ER stress. TLR4-mediated ER stress would therefore display sensitivity to ROS 
scavengers and by extension a subsequent reduction in NEC severity. Another possible 
mechanism of TLR4-mediated injury via increased ER stress centers upon TLR crosstalk 
pathways. Recent work has demonstrated the localization and compartmentalization of TLR3, 
TLR7 and TLR9 into endosomes from the ER is critically dependent upon several proteins 
including the ER-resident protein UNC93B (118,119). Direct interaction between these TLRs 
and UNC93B is a critical step in this process. Disruption in UNC93B function has been 
attributed to defective innate immune responses (120). We have previously identified a 
significant degree of negative crosstalk between TLR4 and TLR9 in IECs. Both receptors are 
reciprocally expressed following exposure of their respective ligands as well as during settings of 
intestinal injury and inflammation (i.e. high TLR4, low TLR9) (113). Therefore, excessive TLR4 
signaling leading to this reciprocal TLR9 expression is correlated to increased ER stress in IECs. 
To date there is, to our knowledge, no evidence, which suggests excessive TLR4 activation 
affects UNC93B function or expression in IECs or any other cell type or tissue. However, should 
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excessive activation of TLR4 lead to dysfunction or decreased expression of UNC93B, or other 
proteins important for ER-endosomal transport, TLR9 nascent peptide chains may accumulate 
within the ER stimulating the UPR and ER stress. This would serve not only as a mechanism of 
TLR4-mediated ER stress but a novel target of TLR4 signaling and TLR crosstalk. Future work 
examining a role for ER stress will elucidate a previously unrecognized role for disturbances of 
proteostasis in the newborn intestinal epithelium in NEC. Thus suggesting that mechanisms at 
work to reestablish this homeostasis, the HSR and UPR, play central part in intestinal injury and 
repair and at the heart of these pathways, the molecular chaperones of the HSP70 family. 
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4.0	   APPENDIX	  
Appendix figure 31.Transduced IECs express the V5 marker. (A) Non-transduced IECs. (B) LacZ-V5 construct 
transduction. (C) K30A CHIP-V5 transduction. (D) H260Q CHIP-V5 transduction. 
Appendix Figure 32. HS does not inhibit TLR5-mediated NF-kB induction. (A) The TLR5 ligand 
flagellin leads to NF-kB activation and nuclear translocation in IECs that is (B) not prevented by induction of 









Appendix Figure 33.Targeted knockdown of HSP70 via siRNA disrupts Celastrol mediated protection against 
TLR4-mediated IEC apoptosis. Representative confocal photomicrographs of IEC-6 enterocytes treated as indicated
and immunostained for Actin [red] and DAPI [blue] or CC3 [green]. Representative apoptotic cells are indicated by 
arrows. Scale bar, 10 um. * p<0.05 
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